#### **Variation and impact of polygenic hematological traits in monogenic sickle cell disease**

Thomas Pincez,<sup>1,2</sup> Ken Sin Lo,<sup>1</sup> Anne-Laure Pham Hung d'Alexandry d'Orengiani,<sup>3</sup> Melanie E.

Garrett,<sup>4</sup> Carlo Brugnara,<sup>5</sup> Allison E. Ashley-Koch,<sup>4</sup> Marilyn J. Telen,<sup>6</sup>

Frédéric Galactéros,<sup>3</sup> Philippe Joly,<sup>7,8</sup> Pablo Bartolucci,<sup>3</sup> Guillaume Lettre<sup>1,9</sup>\*

1 Montreal Heart Institute, Montréal, Québec, Canada

2 Department of Pediatrics, Division of Pediatric Hematology-Oncology, Charles-Bruneau

Cancer Center, CHU Sainte-Justine, Université de Montréal, Montréal, Québec, Canada

3 Red Cell Genetic Disease Unit, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris

(AP-HP), Université Paris Est, IMRB - U955 - Équipe no 2, Créteil, France

4 Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC, USA

5 Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA

6 Department of Medicine, Division of Hematology, Duke University Medical Center, Durham, NC, USA

7 Unité Fonctionnelle 34445 'Biochimie des Pathologies Érythrocytaires', Laboratoire de Biochimie et Biologie Moléculaire Grand-Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France

8 Laboratoire Inter-Universitaire de Biologie de la Motricité (LIBM) EA7424, Equipe 'Biologie Vasculaire et du Globule Rouge', Université Claude Bernard Lyon 1, Comité d'Universités et d'Etablissements (COMUE), Lyon, France

1

9 Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.

#### **Corresponding author:**

Guillaume Lettre

Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec, H1T 1C8, Canada

514-376-3330

guillaume.lettre@umontreal.ca

#### **ABSTRACT**

Several complications observed in sickle cell disease (SCD) are influenced by variation in<br>hematological traits (HT), such as fetal hemoglobin (HbF) level and neutrophil count. Previous large-scale genome-wide association studies carried out in largely healthy individuals have identified 1000s of variants associated with HT, which have then been used to develop multiancestry polygenic trait scores (PTS). Here, we tested if these PTS associate with HT in SCD patients and can improve the prediction of SCD-related complications. In 2,056 SCD patients, patients and can improve the prediction of SCD-related complications. In 2,056 SCD patients,<br>we found that the PTS predicted less HT variance than in non-SCD African-ancestry individuals. we found that the PTS predicted less HT variance than in non-SCD African-ancestry individuals.<br>This was particularly striking at the Duffy/DARC locus, where we observed an epistatic we found that the PTS predicted less that than in non-SCD since an except, individuals.<br>This was particularly striking at the Duffy/DARC locus, where we observed an epistatic<br>interaction between the SCD genotype and the Du This was particularly striking at the Duffy/DARC locus, where we observed an epistatic<br>interaction between the SCD genotype and the Duffy null variant (rs2814778) that led to a two-<br>fold weaker effect on neutrophil count. associated with complications in SCD. In contrast, we found that a simple PTS for HbF that fold weaker effect on neutrophil count. The training including measured the these rest<br>associated with complications in SCD. In contrast, we found that a simple PTS for HbF that<br>includes only six variants explained a large includes only six variants explained a large fraction of the phenotypic variation (17.1-26.4%),<br>associated with acute chest syndrome and stroke risk, and improved the prediction of vasoassociated with acute chest syndrome and stroke risk, and improved the prediction of vaso-<br>occlusive crises. Using Mendelian randomization, we found that increasing HbF by 4.8% reduces stroke risk by 36% ( $P$  = 0.0008). Taken together, our results highlight the importance of occlusive crisk by 36% (P = 0.0008). Taken together, our results highlight the importance of<br>validating PTS in large diseased populations before proposing their implementation in the validating PTS in large diseased populations before proposing their implementation in the context of precision medicine initiatives. valuating PTS in large diseased populations before proposing their implementation in the<br>context of precision medicine initiatives. context of precision medicine initiatives.

#### **INTRODUCTION**

r<br>1 Polygenic trait scores (PTS) have been developed in an effort to harness the power of largesupport their value in the context of precision medicine initiatives.<sup>1,2</sup> One abundantly discussed<br>limitation of PTS is their poor performance when tested in populations that have different support their value in the context of precision medicine initiatives.<sup>474</sup> One abundantly discussed support their value in the context of precision medicine initiatives.\*/\* One abundantly discussed<br>limitation of PTS is their poor performance when tested in populations that have different<br>ancestral backgrounds than the po ancestral backgrounds than the populations in which they were optimized.<sup>3</sup> Another equally<br>important aspect that has not been as extensively studied is how well PTS, which are normally ancestral backgrounds than the populations in which they were optimized.<sup>3</sup> Another equally<br>important aspect that has not been as extensively studied is how well PTS, which are normally<br>calibrated in "healthy" individuals, calibrated in "healthy" individuals, perform in "diseased" individuals.<sup>4</sup> This is important because<br>PTS could, in theory, be useful to stratify patients into mild or severe categories. For instance, a calibrated in "healthy" individuals, perform in "diseased" individuals." This is important because<br>PTS could, in theory, be useful to stratify patients into mild or severe categories. For instance, a<br>PTS for estimated glom PTS for estimated glomerular filtration rate (eGFR) could help identify hypertensive patients<br>more likely to suffer from kidney failure, but because this PTS<sub>eGFR</sub> would have been developed more likely to suffer from kidney failure, but because this PTS<sub>eGFR</sub> would have been developed in largely normotensive individuals, it is unclear how useful it would be in patients with<br>hypertension. in largely normotensive individuals, it is unclear how useful it would be in patients with

,  $\sqrt{r}$ <br>To add  $\overline{a}$ To address this question, we took advantage of the classic monogenic disorder sickle cell<br>disease (SCD), and explored how this pathology impacts the performance of PTS for<br>hematological traits (HT). SCD, the most frequent disease (SCD), and explored how this pathology impacts the performance of PTS for<br>hematological traits (HT). SCD, the most frequent monogenic disease worldwide, is caused by<br>mutations in the β-globin gene.<sup>5</sup> Despite bein hematological traits (HT). SCD, the model included the monogenic monogeneral training) is called as  $\mu$ <br>mutations in the β-globin gene.<sup>5</sup> Despite being primarily a mature red blood cell disorder, SCD is<br>associated with mutations in the β-globin gene.~ Despite being primarily a mature red blood cell disorder, SCD is<br>associated with a broad range of consequences, both hematological (*e.g.* hemolysis, ineffective<br>erythropoiesis) and extraerythropoiesis) and extra-hematological (*e.g.* inflammatory state, endothelial cell activation).<sup>5,6</sup><br>SCD patients present a wide range of complications such as vaso-occlusive crisis (VOC), acute erythropoiesis) and extra-hematological (*e.g.* inflammatory state, endothelial cell activation)."<br>SCD patients present a wide range of complications such as vaso-occlusive crisis (VOC), acute<br>chest syndrome (ACS), stroke, SCD patients present a wide range of complication and their life expectancy is reduced<br>chest syndrome (ACS), stroke, and end-organ dysfunction, and their life expectancy is reduced chest syndrome (ACS), stroke, and end-organ dysfunction, and their life expectancy is reduced.<br>4

when compared to the general population.<sup>5</sup> Critically, the causes of this clinical heterogeneity<br>are only poorly understood. Critically, the causes of this clinical heterogeneity

HT are among the main factors known to be associated with clinical outcomes in SCD.  $\frac{1}{\sqrt{2}}$ moglobin (HbF) is a major disease modifier, associated with reduction in the occurrence<br>ral complications such as VOC, ACS and death.<sup>7–9</sup> A percentage of HbF > 30% is fetal hemoglobin (HbF) is a major and the anti-surfact modifier modifier of several complications such as VOC, ACS and death.<sup>7-9</sup> A percentage of HbF > 30% is<br>associated with an almost complete absence of complications in associated with an almost complete absence of complications in SCD patients.<sup>10,11</sup> However,<br>most SCD patients have lower HbF levels while not receiving disease-modifying therapy and the associated with an almost complete absence of complications in SCD patients.<sup>19,11</sup> However,<br>most SCD patients have lower HbF levels while not receiving disease-modifying therapy and the<br>risk reduction associated with HbF most SCD parameters is the term into the term in the serving and an page cohorts for some<br>risk reduction associated with HbF has not been quantified in large cohorts for some<br>complications such as stroke. Several other HT complications such as stroke. Several other HT have been associated with SCD-related<br>complications, notably elevated white blood cell (WBC) and neutrophil counts with complications, notably elevated white blood cell (WBC) and neutrophil counts with<br>survival,<sup>7,12,13</sup> low hemoglobin levels with composite severe outcomes and death,<sup>13,14</sup> and survival,<sup>7,12,13</sup> low hemoglobin levels with composite severe outcomes and death,<sup>13,14</sup> and platelet count with ACS.<sup>15</sup> survival,''<sup>14,13</sup> low hemoglobin levels with composite severe outcomes and death,<sup>13,14</sup> and<br>platelet count with ACS.<sup>15</sup><br> platelet count with ACS.<sup>15</sup><br>Here, we investigated if PTS for HT developed in largely healthy cohorts also associate

 $\overline{a}$ with blood-cell phenotypes in SCD patients. Furthermore, we evaluated the clinical relevance of these PTS in terms of predicting complications in this patient population. these PTS in terms of predicting complications in this patient population.

#### **SUBJECTS AND METHODS**

#### Populations

We collected data from three SCD cohorts with genome-wide genotype information available:<br>the Cooperative Study of Sickle Cell Disease (CSSCD,  $n = 1278$ ),<sup>16</sup> Genetic Modifier (GEN-MOD, n = 406),<sup>17-19</sup> and Mondor/Lyon (n = 372)<sup>20</sup> (**Table S1**). Data collection was made according to the<br>Helsinki declaration and the study was approved by the institutional ethics committees. DNA genotyping has been described elsewhere<sup>18,21</sup> and we used reference haplotypes from the genotyping has been described elsewhere<sup>18,21</sup> and we used reference haplotypes from the<br>TOPMed project<sup>22</sup> to impute missing genotypes. Eight to 14 hematological traits were genotyping has been described elsewhere<sup>18,21</sup> and we used reference haplotypes from the<br>TOPMed project<sup>22</sup> to impute missing genotypes. Eight to 14 hematological traits were<br>measured at steady state and available in these measured at steady state and available in these SCD cohorts. All patients were at > 3 months<br>from a blood transfusion and only ten patients were taking hydroxyurea at baseline. For measured at steady state and at all all interests constructing pattents in the summarism.<br>From a blood transfusion and only ten patients were taking hydroxyurea at baseline. For<br>comparison, we also accessed data from Afric from a blood transfusion and only ten patients were taking hydron, and a baseline. For<br>comparison, we also accessed data from African-ancestry individuals from the BioMe cohort<sup>23,24</sup><br>and the UK Biobank.<sup>25</sup> comparison, we also accessed data from African-ancestry individuals from the BioMe cohort<sup>25,24</sup><br>and the UK Biobank.<sup>25</sup><br>. and the UK Biobank.<sup>25</sup>

#### PTS for HT

 $\frac{1}{2}$ For all HT except HbF, we used the multi-ancestry PTS derived by the Blood-Cell Consortium to<br>test for association with HT.<sup>23</sup> Briefly, these PTS considered the effect sizes of variants that reach genome-wide significance in multi-ancestry meta-analyses of 746,667 individuals,<br>including 15,171 African-ancestry participants. We generated additive PTS for each individual reach genome-mise significance in multi-ancestry meta-analyses of 746,627 individual<br>including 15,171 African-ancestry participants. We generated additive PTS for each individual<br>and HT by calculating the sum of HT-increas including 15,171 African-ancestry participants. We generated additive PTS for each individual<br>and HT by calculating the sum of HT-increasing alleles weighted by the corresponding genome-<br>wide association study (GWAS) effec conditional effect sizes of six variants at three loci (BCL11A, HBS1L-MYB, HBB) associated with conditional effect sizes of six variants at three loci (BCL11A, HBS1L-MYB, HBB) associated with conditional effect sizes of six variants at three loci (BCL11A, HBS1L-MYB, HBB) associated with

HbF levels in SCD patients.<sup>26–28</sup> We tested the association between normalized PTS and HT by<br>linear regression with the four first principal components as covariables.

## $\sim$  GWAS of HT in SCD patients as covariables. GWAS of HT in SCD patients

 $\frac{1}{\sqrt{2}}$ We adjusted HT for sex and age, and then applied inverse normal transformation. We<br>performed GWAS for each HT available in the three SCD cohorts separately using RvTests ( $v20190205$ )<sup>29</sup> testing an additive genetic model and correcting for the 10 first principal components. We then performed a meta-analysis of the GWAS results using METAL.<sup>30</sup>

For the Duffy/DARC null variant (rs2814778) association with neutrophil and WBC  $\overline{a}$ counts, we compared the additive and recessive models in each cohort, correcting each model<br>for the 10 first principal components. We calculated the effect of rs2814778 on raw neutrophil counts, we compared the additive and recessive models in each convergences conductive and<br>for the 10 first principal components. We calculated the effect of rs2814778 on raw neutrophil<br>and WBC counts using a recessive mode for the 10 first principal components.<br>The 10 first principal components as<br>Covariates. We computed the variance explained in each cohort by rs2814778 using the  $\mu$ and WBC counts using a recessive model with age, sex and the 10 model with a respective as<br>covariates. We computed the variance explained in each cohort by rs2814778 using the<br>following formula: 2pq $\beta^2$ , where p is following formula:  $2pq\beta^2$ , where p is the frequency of the effect allele, q is 1-p and  $\beta$  is the normalized effect size of the effect allele on the HT. normalized effect size of the effect allele on the HT.  $\frac{1}{2}$ , where effect allele on the HT.

To replicate the association between rs113819343, rs8090527 and platelet count, we  $\frac{1}{2}$ analyzed 333 SCD patients from the Duke University Outcome Modifying Genes (OMG) cohort with whole-genome sequencing data available. We performed the association test as described<br>above.  $w = \frac{1}{2}$  with  $\frac{1}{2}$  above.

#### Comparing effect sizes of HT-associated SNPs in SCD patients and non-SCD individuals

For each SNP-HT pair considered in the multi-ancestry PTS models, we retrieved association<br>results from the SCD meta-analyses (above) and the published non-SCD multi-ancestry meta-<br>analyses from the Blood-Cell Consortium.<sup></sup> could recover results for 4,201 (93%) of them in the SCD meta-analyses. From this dataset, we analyses from the Blood-Cell Consortium.<sup>23</sup> While there are 4,502 SNP-HT pairs in the PTS, we<br>could recover results for 4,201 (93%) of them in the SCD meta-analyses. From this dataset, we<br>corrected for multiple testing by connains for a could recover recover  $\frac{1}{2}$ ,  $\frac{1}{2}$  is the main in the SCD meta-analyses. From this dataset, we<br>computed a q-value from the *P-diff* obtained (see *statistical analyses* section below). computed a q-value from the P-diff obtained (see statistical analyses section below).

# computed a q-value from the P-diff obtained (see statistical analyses section below). Association between HT or PTS with SCD-related clinical outcomes

We limited our analyses of the association between PTS and outcomes (VOC rate, ACS rate, stroke) to the large COSSCR manner, we can, considered PTS that were nominally accounted.<br>With the corresponding HT (P < 0.05). First, we fitted Cox proportional hazard ratio models (for<br>stroke) or quasi-Poisson regression stroke) or quasi-Poisson regression models (for VOC and ACS rates) for the outcome on each HT<br>(measured value), adjusting for age, sex and SCD subtype. Second, we repeated these analyses) strone) or quasi-Poisson regression models (for VOC and ACC rates) for the outcome on each HT<br>(measured value), adjusting for age, sex and SCD subtype. Second, we repeated these analyses<br>after replacing the HT by the corre (measured value), adjusting for age, set and SCD subtyper second, we repeated these analyses<br>after replacing the HT by the corresponding PTS. To determine if the PTS improves model<br>prediction beyond the measured HT, we per prediction beyond the measured HT, we performed an analysis of deviance. The difference<br>between the residual deviances of the two models follows a  $\chi$ 2 distribution with n degrees of  $p$  rediction beyond the measured HT, we performed an analysis of assumed the ministence.<br>Between the residual deviances of the two models follows a  $\chi$ 2 distribution with n degrees of<br>freedom, where *n* corresponds to t  $\int_0^\infty$ <br>freedom, where  $n$  corresponds to the difference in the number of degrees of freedom of the<br>two models (i.*e*. one degree of freedom when adding the PTS). two models *(i.e.* one degree of freedom when adding the PTS).

two models (i.e. one degree of freedom when adding the PTS).<br>Mendelian Randomization (MR)  $\frac{1}{\sqrt{2}}$ Mendelian Randomization (MR)

complications. We focused on the following combinations of HT and complications: WBC and<br>neutrophil counts for survival, and HbF for VOC, ACS and stroke (for VOC and ACS, we complications. We found the form of the transment<br>neutrophil counts for survival, and HbF for VOC, ACS and stroke (for VOC and ACS, we<br>dichotomized the data as no event vs. at least one event). dichotomized the data as no event vs. at least one event).

Association between SNPs and HT were performed in the GEN-MOD cohort (linear regression  $\frac{1}{2}$ adjusting for sex and age), whereas association between SNPs and complications were carried out in the CSSCD (logistic regression, adjusting for sex, age and SCD subtype). For WBC and<br>neutrophil counts, we used as instruments genome-wide significant SNPs reported by the out in the CSSCD (regression, adjusting for sex, age and SCD substitute the substitution<br>neutrophil counts, we used as instruments genome-wide significant SNPs reported by the<br>Blood-Cell Consortium<sup>23</sup> and used in the PTS Blood-Cell Consortium<sup>23</sup> and used in the PTS analyses described above. To ensure that these<br>Variants were independent, we further pruned them using PLINK1.9b6.10 ( $r^2 > 0.01$  within 5-Mb Blood-Cell Consortium<sup>23</sup> and used in the PTS analyses described above. To ensure that these<br>variants were independent, we further pruned them using PLINK1.9b6.10 ( $r^2 > 0.01$  within 5-Mb<br>windows).<sup>31</sup> For HbF, we selecte variants were independent, we further pruned them using PLINK1.9b6.10 (r  $>$  0.01 within 9-Mb<br>windows).<sup>31</sup> For HbF, we selected as instruments the six SNPs used in the PTS analyses.<br>Although there is residual linkage dise  $\overline{a}$ Although there is residual linkage disequilibrium between some of these HbF variants, we performed conditional analyses to obtain adjusted effects sizes and standard errors.

We performed all MR analyzes in RStudio (version 1.2.5033) using the TwoSampleMR package  $\overline{a}$ (version 0.5.5).<sup>32</sup> We used the multiplicative random-effect inverse variance-weighted (IVW) approach as the main method for each MR analysis, but we also performed MR-Egger and weighted-median methods as sensitivity analyses. We assessed the validity of our statistically significant results by testing for horizontal pleiotropy (using the MR-Egger intercept test) and significant results by testing  $\frac{1}{2}$  in the MR-Fegger intercept test intercept testing the MR-Egger intercept test of  $\frac{1}{2}$  and  $\frac{1}{2}$  statistics). heterogeneity (using Cochran's Q and I<sup>2</sup><br>Interval<br>Intervals statistics).

#### Statistical analyses

To compare effect sizes derived from the meta-analyses, we calculated heterogeneity P-values<br>(*P-diff*) based on the following t statistic:<sup>33</sup> (*P-diff*) based on the following t statistic:  $33$ 

$$
=\frac{scD - non-sCD}{\sqrt{\frac{2}{scD} + \frac{2}{non-sCD} - 2.SE_{SCD}.E_{non-sCD}}}
$$

 $\frac{1}{r}$ where  $b_{\text{SCD}}$  and  $b_{\text{non-SCD}}$  are the normalized effect sizes in SCD and non-SCD cohorts,<br>respectively; SE<sub>SCD</sub> and SE<sub>non-SCD</sub> are the standard errors in SCD and non-SCD cohorts respectively, and  $r$  is the Spearman rank correlation coefficient computed using effect sizes (for the same effect allele) of all SNPs available in the meta-analyses. In our datasets, r ranged from -0.0016 to 0.0007 across different HT. From the t statistic, we can calculate a P-value using the<br>normal distribution. -0.0016 to 0.0007 across different HT. From the t statistic, we can calculate a P-value using the<br>normal distribution.

All statistical analyses were performed using RStudio (version 1.2.5033) or GraphPad Prism  $\frac{1}{\sqrt{2}}$ All statistical analyses were performed using RSTARE (version 2.2.5) or GraphPad Software, LLC, CA).  $(v_1, \ldots, v_n)$  and  $(v_1, \ldots, v_n)$ .

#### **RESULTS**

#### Performance of hematological PTS in SCD patients

We investigated the phenotypic variance explained by PTS of HT in African-ancestry SCD<br>patients from three cohorts (CSSCD, GEN-MOD, Mondor/Lyon) and in non-SCD African-<br>American individuals from BioMe not included in the d as well as non-SCD African-ancestry individuals from the UK Biobank. These PTS were derived as well as non-SCD African-ancestry individuals from the UK Biobank. These PTS were derived<br>from large multi-ancestry GWAS meta-analyses involving > 700,000 participants.<sup>23</sup> In SCD from large multi-ancestry GWAS meta-analyses involving > 700,000 participants.<sup>23</sup> In SCD<br>participants, the PTS were significant (*P*-value < 0.05) in at least one cohort for nine of the 12 participants, the PTS were significant (*P*-value < 0.05) in at least one cohort for nine of the 12<br>HT tested (Table 1). The non-significant PTS were for hematocrit, hemoglobin concentration participants, the PTS were significant (P-value < 0.05) in at least one conort for nine of the 12<br>HT tested (Table 1). The non-significant PTS were for hematocrit, hemoglobin concentration<br>and lymphocyte count. The varianc and lymphocyte count. The variance explained by significant PTS ranged from 1.0 to 4.0% for<br>RBC traits, 0.9 to 3.9% for WBC traits, and 0.6 to 4.0% for PLT traits. When we compared the RBC traits, 0.9 to 3.9% for WBC traits, and 0.6 to 4.0% for PLT traits. When we compared the<br>performance of these PTS in SCD participants and non-SCD African-ancestry individuals, we RBC traits, the contract traits and your Press for the compared traits in the compared the<br>performance of these PTS in SCD participants and non-SCD African-ancestry individuals, we<br>found that all the 9 PTS with significant performance of these PTS with significant association explained less phenotypic variance in SCD<br>participants (**Table 1** and **Figure 1**). One of the most striking differences was for WBC and found the 9 PTS of the 9 PTS with the 9 participants (Table 1 and Figure 1). One of the most striking differences was for WBC and<br>19 neutrophil counts: the mean variance explained was 2.2% and 3.3% in SCD participants and participants (Table 1 and Figure 1). One of the most striking differences was for WBC and<br>neutrophil counts: the mean variance explained was 2.2% and 3.3% in SCD participants and<br>10.3% and 11.9% in non-SCD individuals, res 10.3% and 11.9% in non-SCD individuals, respectively (Figure 1).

HbF levels are an important modifier of severity in SCD. Because it is rarely measured in  $\overline{a}$ large non-SCD cohorts, the genetics of this trait has not been extensively studied in very large sample sizes. However, smaller GWAS in SCD patients have identified robust associations<br>between HbF levels and genetic variants at three loci: *BCL11A, HBS1L-MYB* and the β-globin between HbF levels and genetic variants at three loci: *BCL11A, HBS1L-MYB* and the β-globin<br>locus (reviewed in ref. <sup>34</sup>). With this information, we derived an HbF PTS that includes six between HbF levels and genetic variants at three loci. BCL11A, HBS1L-MYB and the β-globin<br>locus (reviewed in ref. <sup>34</sup>). With this information, we derived an HbF PTS that includes six locus (reviewed in ref. <sup>34</sup>). With this information, we derived an HbF PTS that includes six<br>11

11

conditionally independent variants (Methods and Table S2). This HbF PTS was strongly<br>associated with HbF levels in all three SCD cohorts, and explained 17.1-26.4% of the variance<br>(Table 1).  $\begin{equation*} \mathsf{Table 1}. \end{equation*}$ 

(Table 1). SCD partially masks the genetic effect of the Duffy/DARC null variant on WBC and neutrophil counts

To understand why the PTS under-performed in SCD patients, we carried out meta-analyses of<br>GWAS results for the 11 HT in the three SCD cohorts, and compared effect sizes ( $\beta_{\text{SCD}}$ ) for the<br>SNPs found in the PTS (4,201 analyses ( $\beta_{\text{non-SCD}}$ , ref. <sup>23</sup>). Across all SNPs and HT, normalized effect sizes were weakly correlated when considering the same effect alleles (Pearson's  $r$  = 0.09, P = 2.4x10<sup>-0</sup>, **Figure** analyses (β<sub>non-ScD</sub>, ret. <sup>23</sup>). Across all SNPs and HT, normalized effect sizes were weakly<br>correlated when considering the same effect alleles (Pearson's  $r = 0.09$ ,  $P = 2.4 \times 10^{-10}$ , **Figure**<br>**2A**). Among the 273 vari correlated when considering the same effect alleles (Pearson's  $r$  = 0.09,  $P$  = 2.4x10  $^{26}$ , **Figure**<br>2A). Among the 273 variant-HT pairs that were nominally associated in SCD meta-analyses (*P-*<br>value < 0.05), 162 (59 2A). Among the 273 variant-HT pairs that were nominally associated in SCD meta-analyses ( $P = 0.002$ , binomial test). value  $\times$  0.05), 162 (59.3%) had a concordant direction of effect in non-SCD meta-analyses (P =<br>0.002, binomial test). 0.002, binomial test).<br>After correction for multiple testing (q-value < 0.05), we found two HT-associated

 $\overline{a}$ After correction for multiple testing (q-value stress) we found the two december<br>s significantly associated with HT in SCD patients, but that also had a significantly<br>nt effect size when comparing  $\beta_{\text{SCD}}$  and  $\beta_{\text{non$  $\sigma$ <br>different effect size when comparing  $\beta_{\textrm{sCD}}$  and  $\beta_{\textrm{non-sCD}}$  : rs8090527 and rs2814778 (Table S3). We<br>did not explore the association between the intergenic rs8090517 variant and platelet count did not explore the association between the intergenic rs8090517 variant and platelet count<br>further as we could not replicate it in an independent SCD cohort (Table S3). The second variant did not explore the association between the intergent reserved. The interaction plattice relations further as<br>further as we could not replicate it in an independent SCD cohort (Table S3). The second variant<br>is the previous further as we could not replicate it in an independent SCD cohort (Table 33). The second variant<br>is the previously described Duffy/DARC null variant (rs2814778),<sup>35</sup> and had a two-fold weaker<br>effect on neutrophil count in effect on neutrophil count in SCD when compared to non-SCD individuals. Based on this effect on neutrophil count in SCD when compared to non-SCD when compared to non-SCD individuals. Based on this

observation, we wondered if the apparent poor performance of the WBC and neutrophil counts observation, we wonder the settion of the Suffy (DARC null variant in this<br>PTS in SCD participants was due to the lower impact of the Duffy /DARC null variant in this<br>patient population. In non-SCD individuals, removing th patient population. In non-SCD individuals, removing the PTS variants on chromosome 1 (to<br>ensure that the large admixture signal due to the Duffy/DARC locus does not impact the ensure that the large admixture signal due to the Duffy/DARC locus does not impact the<br>analysis) reduced the mean variance explained for WBC from 10.3% to 1.6%, and for enalysis) reduced the mean variance explained for WBC from 10.3% to 1.6%, and for<br>neutrophils from 11.9% to 0.9% (Table 1 and Figure 2B). When we repeated this analysis in SCD analysis) reduced the mean variance explained for WBC from 2000 to 2009, and for<br>neutrophils from 11.9% to 0.9% (Table 1 and Figure 2B). When we repeated this analysis in SCD<br>participants, the PTS for WBC was not affected participants, the PTS for WBC was not affected (from 2.1% to 1.9%), whereas the variance explained by the neutrophil count PTS changed slightly from 3.3% to 2.2% (Figure 2B).

Next, we specifically focused on the association between Duffy/DARC rs2814778 and  $\overline{a}$ WBC or neutrophil counts in SCD and non-SCD individuals. For these analyses, we used 6,627<br>African-ancestry participants from the UK Biobank. First, consistent with the recessive MBC or neutrophil counts in SCD and non-SCD individuals. First, consistent with the recessive<br>African-ancestry participants from the UK Biobank. First, consistent with the recessive<br>inheritance of the Duffy-negative blood African-ance of the Duffy-negative blood group, we showed that a recessive genetic model<br>African-ance of the Duffy-negative blood group, we showed that a recessive genetic model<br>provided a better fit with the data than the inheriance of the Duffy-negative areas group, we showed that a recessive generative and<br>provided a better fit with the data than the standard additive model (Table S4). Thus, we used a<br>recessive model for all subsequent ge provided a better fit with the data than the standard additive model (Table 34). Thus, we used a<br>recessive model for all subsequent genetic analyses of this variant. For non-SCD individuals, the<br>single Duffy/DARC variant e single Duffy/DARC variant explained 18.4-23.1% of the phenotypic variance (Table 2). In<br>contrast, the associations between rs2814778 and WBC or neutrophil counts were either weak single Duffy/DARC variant explained 18.4-23.1% of the phenotypic variance (Table 2). In<br>contrast, the associations between rs2814778 and WBC or neutrophil counts were either weak<br>or non-significant in SCD participants, wit or non-significant in SCD participants, with this variant contributing only 0.9-3.3% of the<br>variance in these HT (**Table 2**). To quantify the magnitude of the difference in effect sizes and variance in these HT (Table 2). To quantify the magnitude of the difference in effect sizes and<br>provide meaningful clinical estimates, we calculated that the Duffy null genotype (homozygosity for the C-allele at rs2814778) was associated with a mean reduction of 0.76x10<sup>9</sup> provide meaning meaning of the C-allele at rs2814778) was associated with a mean reduction of 0.76x10<sup>9</sup><br>WBC/L (P = 0.004) and 0.84x10<sup>9</sup> neutrophils/L (P = 1.6x10<sup>6</sup>) in the CSSCD, and of 1.9x10<sup>9</sup> WBC/L (homozygosity for the C-allele at rs2814778) was associated with a mean reduction of 0.76x10°<br>WBC/L (P = 0.004) and 0.84x10<sup>9</sup> neutrophils/L (P = 1.6x10<sup>-6</sup>) in the CSSCD, and of 1.9x10<sup>9</sup> WBC/L WBC/L ( $P = 0.004$ ) and  $0.84 \times 10^9$  neutrophils/L ( $P = 1.6 \times 10^9$ ) in the CSSCD, and of  $1.9 \times 10^9$  WBC/L<br>13

( $P = 3.3 \times 10^{164}$ ) and 1.6x10<sup>9</sup> neutrophils/L ( $P = 4 \times 10^{199}$ ) in the UK Biobank. When we considered<br>both SCD status and the Duffy blood group, we found that: (1) SCD has the strongest impact on neutrophil count, (2) Duffy has a weaker effect on neutrophil count in SCD patients, and (3) the neutrophil PTS (without chromosome 1 variants) remains associated with neutrophil count in<br>all groups (Figure 2C). To further illustrate how SCD modifies the effect of Duffy, we considered neut proups (Figure 2C). To further illustrate how SCD modifies the effect of Duffy, we considered<br>the neutrophil PTS (without chromosome 1 variants) quintiles and compared neutrophil count all groups (Figure 2C). To further mustrate how SCD modifies the effect of Duffy, we considered<br>the neutrophil PTS (without chromosome 1 variants) quintiles and compared neutrophil count<br>in Duffy-positive individuals with the neutrophil Prophil Promosome 2 variants) quintiles and compared neutrophiles and country<br>in Duffy-positive individuals with a PTS in the lowest quintile with Duffy-negative individuals<br>with a PTS in the highest quintil in Duffy-positive in the highest quintile (**Figure 2D**). Whereas in non-SCD UK Biobank participants<br>Duffy outweighs the PTS effect, it is equivalent in SCD patients. Put together, our data suggest Duffy outweighs the PTS effect, it is equivalent in SCD patients. Put together, our data suggest that SCD partially masks the strong effect of the *Duffy*/DARC null variant (rs2814778) on<br>neutrophil count. Finally, we investigated whether sickle cell trait (heterozygosity for the HbS that SCD partially masks the strong effect of the Duffy/DARC fram variant (152014778) on<br>neutrophil count. Finally, we investigated whether sickle cell trait (heterozygosity for the HbS<br>allele) also modified the Duffy/DARC neutrophil count of the United Westigated Whether side can have (heterosygosity for the HbS<br>allele) also modified the Duffy/DARC effect on neutrophil count. We did not find a significant<br>interaction between these two genot interaction between these two genotypes in the UK Biobank (P = 0.327), suggesting that the<br>epistatic effect is specific to SCD (i.e. homozygous HbS). interaction between these two generalisms are the EU Biobank (P = 0.327), suggesting that the<br>epistatic effect is specific to SCD (i.e. homozygous HbS).

## epistatic effect is specific to the first through  $\mathcal{E}(\mathcal{E})$ .<br>GWAS of HT in SCD patients GWAS of HT in SCD patients

 $\frac{1}{1}$ To determine if new genetic variation could specifically modulate HT variation in SCD, we<br>carried out GWAS for 11 blood-cell traits across all three SCD cohorts available (Methods). Given the relatively small sample size of the dataset, we restricted our analyses to variants with a minor allele frequency (MAF) > 1%. We found little evidence of association, except for<br>hematocrit and hemoglobin levels (Figure S1). We found 24 genome-wide significant (P < 5x10 hematocrit and hemoglobin levels (**Figure S1**). We found 24 genome-wide significant ( $P < 5 \times 10^{-8}$ ) SNP-HT associations, including 23 at the known HbF loci and associated with hemoglobin hematocrit and hemoglobin levels (**Figure S1**). We found 24 genome-wide significant (*P <* 5x10<br><sup>8</sup>) SNP-HT associations, including 23 at the known HbF loci and associated with hemoglobin<br>- $\overline{a}$ ) snc including 23 at the known HbF loci and associated with hemoglobing  $14$  levels, hematocrit, or RBC count (**Table S5**). The last variant, rs113819343, was associated with<br>platelet (PLT) count in the SCD meta-analyses ( $P = 1.4 \times 10^{-8}$ ). This variant is common in Africanancestry individuals (MAF = 5.5%, gnomAD) but rarer in European-ancestry populations (MAF = 0.098%). This variant is not associated with PLT count in the multi-ancestry (P = 0.72, N = 473,895) nor African-specific (P = 0.27, N = 15,171) meta-analyses from the Blood-Cell 0.098%). This variant is not associated with FLT count in the multi-ancestry (P = 0.72, N = 173,895) nor African-specific ( $P = 0.27$ ,  $N = 15,171$ ) meta-analyses from the Blood-Cell<br>Consortium.<sup>23</sup> Our attempt to replicate  $473,835$ ) nor African specific  $\binom{P}{P}$  = 0.27,  $\binom{N}{P}$  = 15,171) meta-analyses from the Blood-Cell<br>Consortium.<sup>23</sup> Our attempt to replicate this association with PLT count in 333 SCD patients from<br>the OMG cohort wa the OMG cohort was unsuccessful ( $P = 0.69$ ), so it is not possible to conclude if this association<br>is real or a false positive result. the OMG cohort was unsuccessful ( $P = 0.69$ ), so it is not possible to conclude if this association<br>is real or a false positive result.

## is real or a false positive result.<br>Associations between hematological PTS and SCD-related complications

 $\frac{1}{\sqrt{2}}$ Variation in HT has been associated (prospectively) with several clinical outcomes observed in<br>SCD patients such as death,<sup>7</sup> stroke,<sup>36</sup> VOC,<sup>8</sup> and ACS.<sup>9</sup> We could reproduce most of those SCD patients such as death,' stroke,<sup>36</sup> VOC,<sup>8</sup> and ACS.<sup>9</sup> We could reproduce most of those<br>results in the genotyped subset of the CSSCD (**Table S6**). Having established that multi-ancestry<br>PTS are associated with HT in results in the genotyped subset of the CSSCD (Table S6). Having established that multi-ancestry<br>PTS are associated with HT in SCD participants (although to a lesser extent than in non-SCD<br>individuals), we asked if they wer PTS are accounted with the model participants (anticagn to a lesser enterminant in non-score<br>individuals), we asked if they were also associated with these complications in the CSSCD. For<br>these analyses, we used nominally these analyses, we used nominally significant PTS (Table 1) for which the corresponding HT was<br>also significantly associated with the complication (Table S6). In total, we tested six PTSthese analyses, we used nominally significant PTS (Table 1) for which the corresponding HT was<br>also significantly associated with the complication (Table S6). In total, we tested six PTS-<br>complication combinations, and fou also significantly associated with the complication (Table 30). In total, we tested six PTS-<br>complication combinations, and found significant associations for  $PTS_{Hbf}$ -stroke and  $PTS_{Hbf}$ -ACS<br>(Table 3). complication combinations, and found significant associations for PTSHB-stroke and PTSHB-stroke and PTSHB-stroke and PTSHB-stroke and PTSHBF-stroke and PTSHBF-stroke and PTSHBF-ACSS (PTSHBF-ACSS).

(Table 3).<br> $W_{\ell}$  $\overline{a}$ We extended these analyses to determine if the PTS could improve the predictive<br>performance of the models beyond the baseline HT measures. We reasoned that because the performance of the models between the models between the baseline HT measures. We reasoned that because that because the baseline  $\frac{1}{16}$ 

PTS capture HT heritable variation, they would more faithfully represent "life-long exposure"<br>and add information that is independent from HT lab measure imprecisions. The models did not<br>improve for stroke and ACS rate, bu improve for stroke and ACS rate, but we found that PTS<sub>HbF</sub> improved the prediction of VOC,<br>consistent with previous reports (T<mark>able 3</mark>).<sup>37,38</sup> Interestingly, additional analyses revealed that  $\mu$ <sub>mprove</sub> for stroke and ACS rate) with the found that PTS<sub>HbF</sub> improved the predictions reports (Table 3).<sup>37,38</sup> Interestingly, additional analyses revealed that PTS<sub>HbF</sub> improved the prediction of VOC in patients wi PTS<sub>HbF</sub> improved the prediction of VOC in patients with low HbF lab values (< 10%), levels at which HbF is not associated with VOC (Table S7). For high HbF values ( $> 10\%$ ), HbF is strongly associated with VOC and adding  $PTS_{Hbf}$  did not improve the predictive model.

## میں ہے۔<br>Quantifying the causal impact of HbF levels on SCD complications by MR

 $\frac{1}{1}$ Finally, we sought to confirm some of the causal effects of HT on SCD complications as reported<br>in the literature: the protection that high HbF levels confer against stroke,  $39,40$  ACS<sup>9</sup> and VOC,  $8$ in the literature: the protection that high HbF levels confer against stroke,<sup>39,46</sup> ACS<sup>3</sup> and VOC, <sup>8</sup><br>as well as the increased risk of death associated with high WBC<sup>7</sup> and neutrophil counts.<sup>41</sup> To<br>this end, we perform as well as the increased risk of death associated with high WBC' and neutrophil counts.<sup>44</sup> To<br>this end, we performed two-sample MR using the pseudo-independent SNPs from the PTS of<br>HbF, WBC and neutrophils (M<mark>ethods</mark>). We the stray the performation cample this large are persons made the performed the proof of the proof.<br>HbF, WBC and neutrophils (Methods). We found a causal association between HbF and stroke:<br>a one standard deviation increas HbT, WBC and neutrophils (Methods). We found a causal association between HbT and stroke:<br>a one standard deviation increase in genetically-determined HbF levels (corresponding to 4.8%<br>of HbF) decreases by 36% the risk of s of HbF) decreases by 36% the risk of stroke (odds ratio [95% confidence interval] = 0.64 [0.49-<br>0.83], P = 0.0008, Figure 3). Although the direction of the effect was similar using MR-Egger and of HaF) decreases by 36% are not stroke (onderland (our confidence interval) = 0.09 (onder<br>0.83], P = 0.0008, Figure 3). Although the direction of the effect was similar using MR-Egger and<br>weighted median, these analyzes w  $0.83$ <sub>J</sub>,  $P = 0.0000$ , Figure 3). Although the direction of the effect was similar using MR-Egger and<br>weighted median, these analyzes were not statistically significant, suggesting insufficient power<br>(Table S8). We found (Table S8). We found no heterogeneity in the effect  $I^2 = 0$ %) and confirmed the absence of (Table S8). We found no heterogeneity in the effect (I<sup>e</sup> = 0%) and confirmed the absence of<br>horizontal pleiotropy (Egger intercept, -0.07, *P* = 0.75). All other MR tests were non-significant<br>(Table S8). horizontal pleiotropy (Egger intercept,  $(0.07, P = 0.75)$ . All other MR tests were non-significant<br>(Table S8).  $(Tab)$   $\in$   $SO(3)$ .

#### **DISCUSSION**

In this study, we showed that PTS for HT derived in here 202 individuals largely showelp solven to<br>When tested in SCD patients. We hypothesize that this is due to an epistatic effect of the SCD<br>genotype on the large number when tested in the patients. We hypothesize that this is an epistatic enterty in the set<br>genotype on the large number of variants that contribute to polygenic variation in HT. In<br>particular, we found a dramatic impact of S particular, we found a dramatic impact of SCD on the magnitude of the effect of the Duffy/DARC null rs2814778 variant on neutrophil count. Potentially because the phenotypic<br>variance explained by these PTS for HT remain low, we could not detect an effect of these PTS Duffy/DARC null 132014778 variant on neutrophil count. Potentially because the phenotypic<br>variance explained by these PTS for HT remain low, we could not detect an effect of these PTS<br>on disease expressivity when consideri ر<br>on disease expressivity when considering different SCD-related complications. However, a small<br>set of six HbF-associated variants was useful to predict VOC when considered as a PTS, and to set of six HbF-associated variants was useful to predict VOC when considered as a PTS, and to quantify the causal protective impact of HbF increase on stroke risk reduction.

Several non-mutually exclusive factors could explain why PTS for HT were not as  $\overline{a}$ predictive in SCD patients. These patients have different baseline levels and distribution values for several HT such as hemoglobin and WBC counts. This is in part due to the direct hemolytic<br>effect of hemoglobin S, but also to the broad consequences of SCD such as the induction of a for seffect of hemoglobin S, but also to the broad consequences of SCD such as the induction of a<br>chronic inflammatory state that can lead to cytokines-driven higher WBC count.<sup>42,43</sup> Moreover, effronic inflammatory state that can lead to cytokines-driven higher WBC count.<sup>42,43</sup> Moreover,<br>the frequent intercurrent complications (*e.g.* VOC) experienced throughout SCD natural history the frequent intercurrent complications (e.g. VOC) experienced throughout SCD natural history<br>could result in greater variability in HT values. Finally, SNP genotyping arrays do not capture all the frequent intercurrent compileations (e.g. VOC) experienced throughout SCD hatural history<br>could result in greater variability in HT values. Finally, SNP genotyping arrays do not capture all<br>structural variants, which  $\epsilon$  could result in greater variability in the same of many, sthe genotyping arrays do not capture all<br>structural variants, which are the main alterations in  $\alpha$ -thalassemia, a major determinant of<br>mean corpuscular hemo structural variants, which are the main alterations in a mailer single alternation of<br>mean corpuscular hemoglobin and mean corpuscular volume. Thus, the performance of HT PTS<br>will improve once comprehensive whole-genome se mean corpuscular hemoglobin and mean corpuscular whole-genome sequencing of SCD cohorts becomes<br>available. whole-general improve once comprehensive whole-general control of SCD cohorts becomes available.

17

 $\overline{a}$ The C allele of the Duffy/DARC (also known as *ACKR1*) chemokine reservoir expression<br>gene.<sup>44,45</sup> It has been known that the Duffy/DARC null variant is strongly associated with lower of expression of the Duffy/DARC (also known as ACKR1) chemokine reservoir expression<br>gene.<sup>44,45</sup> It has been known that the Duffy/DARC null variant is strongly associated with lower<br>circulating neutrophil and WBC counts i gene.<sup>44,45</sup> It has been known that the Duffy/*DARC* null variant is strongly associated with lower<br>circulating neutrophil and WBC counts in SCD and non-SCD individuals due to extravasation to<br>tissues,<sup>46–50</sup> and in partic chromain.g neutrophil and WBC counts in SCD and NSW 200 manimum and to entromaintent to<br>tissues,<sup>46–50</sup> and in particular the spleen.<sup>51</sup> Although it is unclear why SCD partially masks the<br>effect of this variant on neutrop tissues, $7^{\circ}$  <sup>55</sup> and in particular the spleen.<sup>54</sup> Although it is unclear why SCD partially masks the<br>effect of this variant on neutrophil count, we may speculate that the precocious and pervasive<br>splenic atrophy obser efference atrophy observed in SCD patients could lead to a reduced reservoir size. Additionally,<br>Various Duffy/DARC variants in non-SCD and SCD individuals have been shown to affect the splents attephy exects in Seculation terms could be a reduced received reservationally,<br>various Duffy/DARC variants in non-SCD and SCD individuals have been shown to affect the<br>binding of DARC with inflammatory markers suc various Burry/BANC variants in non-SCB and SCB individuals have been shown to affect the<br>binding of DARC with inflammatory markers such as interleukin 8.<sup>52–54</sup> Definitive data are still<br>lacking, but the proinflammatory st lacking, but the proinflammatory state of SCD patients may contribute to the discrepancy in  $\text{effect observed.}^{55}$ effect observed.<sup>55</sup><br>Whether or not the Duffy phenotype is associated with complications in SCD patients

 $\overline{r}$ remains unclear.<sup>56–61</sup> The potential consequences of the Duffy/DARC status in SCD would be<br>linked to circulating proinflammatory cytokines and especially the resulting effect on neutrophil remains unclear.<sup>56–64</sup> The potential consequences of the Duffy/*DARC* status in SCD would be<br>linked to circulating proinflammatory cytokines and especially the resulting effect on neutrophil<br>and WBC counts, which has been linked to circulating prominimatory cytomics and supermary are resulting since substance pro<br>and WBC counts, which has been implicated in several SCD complications.<sup>7,12,13</sup> However, our<br>data showed that the Duffy/*DARC* n data showed that the Duffy/DARC negative phenotype is not a good proxy for neutrophil count in SCD patients in contrast to non-SCD individuals in whom it accounts for a large fraction of the<br>phenotypic variance. Thus, while it remains possible that neutrophils causally contribute to SCD in SCD patients in contrast to non-SCD individuals in the model child of a large massive to the<br>phenotypic variance. Thus, while it remains possible that neutrophils causally contribute to SCD<br>clinical heterogeneity, we ha phenote. The<br>clinical heterogeneity, we have not been able to use genetics, including MR, to confirm this<br> clinical heterogeneity, we have not been able to use genetics, including MR, to confirm this

epidemic observation of the relation of the relation of the relation of the relation of the neutrophile-<br>
relation of the neutrophile-associated by the neutrophile-associated by the neutrophile-associated by the neu<br>
in th variants in SCD patients.<br>Although complex multi-ancestry PTS for general HT that included 100s of variants

 $\overline{a}$ performed poorly in SCD patients, we showed that a simple PTS for HbF made of six variants at<br>three loci can capture a large fraction of the phenotypic variance in this important SCD performed poor, we say patiently its situation that a simple reservation that a six variance is three loci can capture a large fraction of the phenotypic variance in this important SCD<br>modifier. One major difference betwee modifier. One major difference between the general HT and HbF is that we developed PTS<sub>HbF</sub><br>using GWAS data from SCD patients. Interestingly, we observed an association between PTS<sub>HbF</sub> and ACS or stroke in the large CSSCD. We validated previous reports that a PTS for HbF can and ACS or stroke in the large CSSCD. We validated previous reports that a PTS for HbF can<br>improve the prediction of VOC,<sup>37,38</sup> and further discovered that this PTS<sub>HbF</sub> was useful in the improve the prediction of VOC, $37,38$  and further discovered that this PTS<sub>HbF</sub> was useful in the<br>subset of patients with HbF levels < 10%. Our limited sample size prevented powerful analyses subset of patients with HbF levels < 10%. Our limited sample size prevented powerful analyses<br>of causality, yet we could use MR to quantify the protective effect of HbF on stroke risk in SCD subset of patients with HabF levels and the tample site prevents powerful analyses<br>of causality, yet we could use MR to quantify the protective effect of HbF on stroke risk in SCD<br>patients, although we acknowledge that the of the Winner's curse could have biased upward our<br>patients, although we acknowledge that the Winner's curse could have biased upward our<br>estimate. This result is consistent with clinical trials that have shown that the Hb estimate. This result is consistent with clinical trials that have shown that the HbF-inducing drug<br>hydroxyurea (HU) can reduce stroke risk in primary prevention in SCD.<sup>62,63</sup> Furthermore, estimate. This result is consistent trial trials that that the Horman trials the Havening artig<br>hydroxyurea (HU) can reduce stroke risk in primary prevention in SCD.<sup>62,63</sup> Furthermore,<br>although HU can improve SCD through hydroxyurea (HU) can reduce stroke risk in primary prevention in SCD.<sup>82,83</sup> Furthermore,<br>although HU can improve SCD through different mechanisms,<sup>64</sup> our MR analysis is useful to<br>partition its effect and specifically qua although HU can improve SCD through different mechanisms, $^{\circ\circ}$  our MR analysis is useful to<br>partition its effect and specifically quantify how genetically-determined (lifelong) HbF levels<br>modulate stroke risk. Given its particle and specifically the constant of the modulate stroke risk. Given its hematological rationale, simplicity, and performance, we believe<br>that the time is right to formally test in a pragmatic randomized clinical tria that the time is right to formally test in a pragmatic randomized clinical trial whether PTS<sub>HbF</sub> is<br>useful to manage clinical heterogeneity in SCD patients. that the time is right to formally test in a pragmatic randomized clinical trial mixture  $\Gamma$  is higher useful to manage clinical heterogeneity in SCD patients. useful to manage clinical heterogeneity in SCD patients.

ouraly<br>The penetrance of monogenic mutations in diseases such as coronary artery disease (CAD) and<br>familial breast and colorectal cancers,<sup>65</sup> much less is known about their effect on expressivity the penetral of these site mutations of the penetral familial breast and colorectal cancers,  $^{65}$  much less is known about their effect on expressivity<br>(or disease severity).<sup>4</sup> This distinction is important because, alt familial breast and colorectal cancers,<sup>65</sup> much less is known about their effect on expressivity<br>(or disease severity).<sup>4</sup> This distinction is important because, although they may not cause the<br>disease, several clinical v (or disease severity).\* This distinction is important because, although they may not cause the<br>disease, several clinical variables and other endophenotypes that are captured by PTS can<br>strongly modify disease severity (*e.* strongly modify disease severity (*e.g.* PTS for kidney functions in the context of hypertension or<br>CAD. PTS for retinopathy/cataract in diabetic patients). Our analyses indicate that simply strongly modify disease severity (e.g. PTS for kidney functions in the context of hypertension or<br>CAD, PTS for retinopathy/cataract in diabetic patients). Our analyses indicate that simply<br>translating the genetics of polyg CAD, PTS for retinopathy/cataract in diabetic patients). Our analyses indicate that simply populations may not provide the expected gain in risk stratification in the context of precision medicine. Fortunately, large biobanks and other cohorts should soon enable powerful GWAS for genetic modifiers in  $> 10,000$  patients who all suffer from the same disease. for generic modifiers in  $-1$ ,  $-1$  patients who all suffer from the same disease.

#### SUPPLEMENTAL DATA

## $\begin{array}{c} \begin{array}{c} \circ \\ \circ \end{array} \end{array}$ DECLARATION OF INTERESTS DECLARATION OF INTERESTS

 $\begin{array}{c} \n\end{array}$ 

### The authors denine in competing interests.<br>ACKNOWLEDGMENTS  $\frac{1}{\sqrt{2}}$ ACKNOWLEDGMENTS

We thank all participants for their contribution to this project. We thank Gabrielle Boucher for<br>statistical support. T.P. is a recipient of a Charles Bruneau Foundation fellowship award and merit scholarship program for foreign students from the Ministry of Education and Higher Education of Quebec. This work was funded by the Canadian Institutes of Health Research (PJT<br>#156248), Bioverativ, a Sanofi Company, and the Canada Research Chair Program (to G.L.). GEN-MOD samples and data collection were supported by NIH grant HL-68922. A.A-K., M.J.T. end the Company, a Sanote Company, and the Canada Research Chair Program (to Chair,<br>GEN-MOD samples and data collection were supported by NIH grant HL-68922. A.A-K., M.J.T.<br>and establishment and analysis of the OMG cohort GEN-MOD SAMPLES and data construct were supported by the grant HDD samples and establishment and analysis of the OMG cohort have been funded by NHLBI (RO1HL68959,<br>HL79915, HL70769, HL87681). This research has been conducte HL79915, HL70769, HL87681). This research has been conducted using the UK Biobank<br>Resource under Application Number 11707. HERRES HERRES, HERRES, HARRISTE, HAN BEEN CONDUCTED USING USING THE UK BIOBANIA<br>Resource under Application Number 11707.

## PRESOURCE UNDER APPLICATION NUMBER 1170<br>DATA AND CODE AVAILABILITY  $\begin{array}{c} \n\end{array}$

ی ہیں ہے۔<br>https://www.ncbi.nlm.nih.gov/gap/), accession phs000366.v1.p1. The UK Biobank dataset is<br>publicly available (<u>https://www.ukbiobank.ac.uk/</u>). The GEN-MOD, Mondor/Lyon and BioMe https://www.nchi.nlm.ningov/gap/), accession phases somaliple. The CEN-MOD and BioMe<br>publicly available (https://www.ukbiobank.ac.uk/). The GEN-MOD, Mondor/Lyon and BioMe publicly available (https://www.ukbiobank.ac.ukbiobank.ac.uk/). The Gen-Mode, ac.uk<br>Model and Biometers.com

21

datasets and code supporting the current study have not been deposited in a public repository<br>because data are not public but are available from the corresponding author on request.

## $\begin{bmatrix} 1 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0$ AUTHOR CONTRIBUTIONS

 $\frac{1}{1}$ T.P. and G.L. designed the study. T.P., K.S.L. and M.E.G. performed the analyses. T.P.,<br>A.L.P.H.A.O., M.E.G, C.B., A.E.A.-K., M.J.T., F.G., P.J., P.B and G.L. collected the clinical and genetic data. T.P. and G.L. drafted the paper. G.L. supervised the study. All authors participated in data interpretation, revised the manuscript for critical content and approved the final<br>manuscript. in data interpretation, revised the manuscript for critical content and approved the final<br>manuscript.

#### REFERENCES

1. Lewis, C.M., and Vassos, E. (2020). Polygenic risk scores: from research tools to clinical instruments. Genome Med. 12, 44.

instruments. Genome Med. 12, 44.<br>2. Sun, J., Wang, Y., Folkersen, L., Borné, Y., Amlien, I., Buil, A., Orho-Melander, M., Børglum,<br>A.D., Hougaard, D.M., Regeneron Genetics Center, et al. (2021). Translating polygenic risk mstruments. Genome Med. 12, 44.<br>2. Sun, J., Wang, Y., Folkersen, L.,<br>A.D., Hougaard, D.M., Regeneron<br>scores for clinical use by estimating A.D., Hougaard, D.M., Regeneron Genetics Center, et al. (2021). Translating polygenic risk<br>scores for clinical use by estimating the confidence bounds of risk prediction. Nat. Commun. 12,<br>5276. scores for clinical use by estimating the confidence bounds of risk prediction. Nat. Commun. 12,<br>5276.<br>3. Martin, A.R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B.M., and Daly, M.J. (2019). Clinical

scores for climear use by estimating the confidence bounds of risk prediction. Nat. Commun. 12,<br>5276.<br>3. Martin, A.R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B.M., and Daly, M.J. (2019). Clinical<br>use of current polygen  $3.$  Marger of

use of current polygenic risk scores may exacerbate health disparities. Nat. Genet. 51, 584–591.<br>4. Oetjens, M.T., Kelly, M.A., Sturm, A.C., Martin, C.L., and Ledbetter, D.H. (2019). Quantifying<br>the polygenic contribution use of carrent porygenic risk scores may exacerbate health disparities. Nat. Genet. 51, 584–591.<br>4. Oetjens, M.T., Kelly, M.A., Sturm, A.C., Martin, C.L., and Ledbetter, D.H. (2019). Quantifying<br>the polygenic contribution the polygenic contribution to variable expressivity in eleven rare genetic disorders. Nat.<br>Commun. 10, 4897.

د (سر 10, 4897)<br>5. Kato, G.J., Piel, F.B., Reid, C.D., Gaston, M.H., Ohene-Frempong, K., Krishnamurti, L., Smith,<br>W.R., Panepinto, J.A., Weatherall, D.J., Costa, F.F., et al. (2018). Sickle cell disease. Nat Rev Dis 5. Kato, G.J., Piel, F.B., Reid, C.D., Gaston, M.H., Ohene-Frempong, K., Krishnamurti, L., Smith, W.R., Panepinto, J.A., Weatherall, D.J., Costa, F.F., et al. (2018). Sickle cell disease. Nat Rev Dis<br>Primers 4, 18010. 1. Kato, G.J., Panepinto, J.A., Weatherall, D.J., Costa, F.F., et al. (2018). Sickle cell disease. Nat Rev Dis<br>Primers 4, 18010.<br>6. Ware, R.E., de Montalembert, M., Tshilolo, L., and Abboud, M.R. (2017). Sickle cell diseas

Primers 4, 18010.<br>Brimers 4, 18010.<br>6. Ware, R.E., de Montalembert, M., Tshilolo, L., and Abboud, M.R. (2017). Sickle cell disease. Lancet 390, 311–323. Framers 4, 18010.<br>6. Ware, R.E., de<br>Lancet 390, 311–3  $\frac{6.666}{290,311-323}$ .<br>Lancet 390, 311–323. Lancet 390, 311–323.

(1994). Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J.<br>Med. 330, 1639–1644.<br>8. Platt, O.S., Thorington, B.D., Brambilla, D.J., Milner, P.F., Rosse, W.F., Vichinsky, E., and

(1994). Med. 330, 1639–1644.<br>1994). Med. 330, 1639–1644.<br>Kinney, T.R. (1991). Pain in sickle cell disease. Rates and risk factors. N. Engl. J. Med. 325, 11– Med. 330, 1833–1844.<br>8. Platt, O.S., Thoring!<br>Kinney, T.R. (1991). Pa<br>16. Kinney, T.R. (1991). Pain in sickle cell disease. Rates and risk factors. N. Engl. J. Med. 325, 11–<br>16.<br>9. Castro, O., Brambilla, D.J., Thorington, B., Reindorf, C.A., Scott, R.B., Gillette, P., Vera, J.C.,<br>and Levv. P.S.

Kinney, T.R. (1991). Fain in sickle cell disease. Rates and risk factors. N. Engl. J. Med. 929, 11–<br>16.<br>9. Castro, O., Brambilla, D.J., Thorington, B., Reindorf, C.A., Scott, R.B., Gillette, P., Vera, J.C.,<br>and Levy, P.S. –<br>9. C<br>and<br>The 9. Castro, O., Brambilla, O., P., Premiser, C., Premiser, C., Castro, C., C., C., C., C., C., 2., 2., 2., 2.,<br>The Cooperative Study of Sickle Cell Disease. Blood 84, 643–649.<br>10. Ngo, D.A., Aygun, B., Akinsheye, I., Hankin

and Levy, Prequesty, President Press syndrome in significant and represents and radio and represent<br>The Cooperative Study of Sickle Cell Disease. Blood 84, 643–649.<br>10. Ngo, D.A., Aygun, B., Akinsheye, I., Hankins, J.S., B The Cooperative Study of Sickle Cell Disease. Blood 84, 643–643.<br>10. Ngo, D.A., Aygun, B., Akinsheye, I., Hankins, J.S., Bhan, I., I<br>Chui, D.H.K. (2012). Fetal haemoglobin levels and haematologic.<br>heterozygotes for haemogl Chui, D.H.K. (2012). Fetal haemoglobin levels and haematological characteristics of compound<br>heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin.<br>Br. J. Haematol. 156, 259–264. Chui, D.H.M. (2022). Fetal haemoglobin Chui, P.H. (2014). Fetal haemoglobin.<br>Br. J. Haematol. 156, 259–264.<br>11. Steinberg, M.H., Chui, D.H.K., Dover, G.J., Sebastiani, P., and Alsultan, A. (2014). Fetal

heterozygotes for harmoglobin 3 and deterotion interacting persistence of fetal harmoglobin.<br>Br. J. Haematol. 156, 259–264.<br>hemoglobin in sickle cell anemia: a glass half full? Blood 123, 481–485. Br. J. Haematol. 156, 255–264.<br>11. Steinberg, M.H., Chui, D.H<br>hemoglobin in sickle cell anemi

hemoglobin in sickle cell anemia: a glass half full? Blood 123, 481–485.<br>12. Sebastiani, P., Nolan, V.G., Baldwin, C.T., Abad-Grau, M.M., Wang, L., Adewoye, A.H.,<br>McMahon, L.C., Farrer, L.A., Taylor, J.G., 6th, Kato, G.J., hemoglobin in sickle cell anemia: a glass half full? Blood 123, 481–485.<br>12. Sebastiani, P., Nolan, V.G., Baldwin, C.T., Abad-Grau, M.M., W<br>McMahon, L.C., Farrer, L.A., Taylor, J.G., 6th, Kato, G.J., et al. (200<br>predict th McMahon, L.C., Farrer, L.A., Taylor, J.G., 6th, Kato, G.J., et al. (2007). A network model to<br>predict the risk of death in sickle cell disease. Blood 110, 2727–2735.<br>13. Elmariah, H., Garrett, M.E., De Castro, L.M., Jonass

predict the risk of death in sickle cell disease. Blood 110, 2727–2735.<br>13. Elmariah, H., Garrett, M.E., De Castro, L.M., Jonassaint, J.C., Ataga, K.I., Eckman, J.R., Ashley-<br>Koch, A.E., and Telen, M.J. (2014). Factors ass 13. Elmariah, H., Garrett, M.E., De Castro, L.M., Jonassaint, J.C., Ataga, K.I., Eckman, J.R., Ashley-

14. Miller, S.T., Sleeper, L.A., Pegelow, C.H., Enos, L.E., Wang, W.C., Weiner, S.J., Wethers, D.L., sickle cell disease cohort. Am. J. Hematol. 89, 530–535.<br>14. Miller, S.T., Sleeper, L.A., Pegelow, C.H., Enos, L.E., Wang, W.C., Weiner, S.J., Wethers, D.L.,<br>Smith, J., and Kinney, T.R. (2000). Prediction of adverse outcom sickle cell disease cohort. Am. J. Hematol. 89, 330–335.<br>14. Miller, S.T., Sleeper, L.A., Pegelow, C.H., Enos, L.E.,<br>Smith, J., and Kinney, T.R. (2000). Prediction of adver:<br>disease. N. Engl. J. Med. 342, 83–89. 14. Miller, S. M., Sureper, S. M., P. Berlin, S. Miller, M. Miller, M. Miller, M. Miller, S. M., S. S., S., S.<br>15. Vichinsky, E.P., Neumayr, L.D., Earles, A.N., Williams, R., Lennette, E.T., Dean, D., Nickerson,

Smith, J., and Tames), T.M. (2000).<br>Smith, J., Med. 342, 83–89.<br>Smith, J., Dean, D., Nickerson, B., Orringer, E., McKie, V., Bellevue, R., et al. (2000). Causes and outcomes of the acute chest disease. N. Engl. 3. Med. 342, 83–89.<br>15. Vichinsky, E.P., Neumayr, L.D., Ea<br>B., Orringer, E., McKie, V., Bellevue,<br>syndrome in sickle cell disease. Nati 15. Vichinsky, E.P., Neumayr, 2007, Entrey and Theorems, A.S., Denversely, 2007, 2008, 2008, 2009, 200 B., Orringer, E., McKie, V., Bellevue, M., Bellevue, Ballevue, R., McKie, Syndrome in Sickle cell disease. National Acute Chest Syndrome Study Group. N. Engl. J. Med.<br>342, 1855–1865.<br>16. Farber, M.D., Koshy, M., and Kinney

syndrome in sind ten ansatt framewing time in signifiantly study of Sickle Cell Disease:<br>342, 1855–1865.<br>Demographic and socioeconomic characteristics of patients and families with sickle cell disease. 342, 1855–1865.<br>16. Farber, M.D., Koshy, M., and Kinney, T.R. (1985). Cooperative Study of Sickle Cell Disease:<br>Demographic and socioeconomic characteristics of patients and families with sickle cell disease.<br>J. Chronic Di Demographic and socioeconomic characteristics of patients and families with sickle cell disease.<br>J. Chronic Dis. 38, 495–505.<br>17. Bartolucci, P., Brugnara, C., Teixeira-Pinto, A., Pissard, S., Moradkhani, K., Jouault, H.,

J. Chronic Dis. 38, 495–505.<br>17. Bartolucci, P., Brugnara, C., Teixeira-Pinto, A., Pissard, S., Moradkhani, K., Jouault, H., and<br>Galacteros, F. (2012). Erythrocyte density in sickle cell syndromes is associated with specif J. Chronic Dis. 38, 435–505.<br>17. Bartolucci, P., Brugnara<br>Galacteros, F. (2012). Eryth<br>clinical manifestations and h 17. Bartolucci, P., Brugnara, P., Penerico Pinto, P., Picci, P., Moranamian, A., Penant, P., and<br>Galacteros, F. (2012). Erythrocyte density in sickle cell syndromes is associated with specific<br>clinical manifestations and h clinical manifestations and hemolysis. Blood 120, 3136–3141.<br>18. Ilboudo, Y., Bartolucci, P., Rivera, A., Sedzro, J.-C., Beaudoin, M., Trudel, M., Alper, S.L.,

clinical manifestations and hemolysis. Blood 120, 3136–3141.<br>18. Ilboudo, Y., Bartolucci, P., Rivera, A., Sedzro, J.-C., Beau 18. Ilboudo, Y., Bartolucci, P., Rivera, P., Rivera, A., S.L., Beaudoin, M., Alper, S.L., A., Alper, S.L., A., A<br>23.

erythrocyte density in sickle cell disease patients. Blood Cells Mol. Dis. 65, 60–65.<br>19. Ilboudo, Y., Garrett, M.E., Bartolucci, P., Brugnara, C., Clish, C.B., Hirschhorn, J.N.,<br>Galactéros, F., Ashley-Koch, A.E., Telen, M erythrocyte density in sickle cell disease patients. Blood Cells Mol. Dis. 65, 60–65.<br>19. Ilboudo, Y., Garrett, M.E., Bartolucci, P., Brugnara, C., Clish, C.B., Hir<br>Galactéros, F., Ashley-Koch, A.E., Telen, M.J., and Lettr Galactéros, F., Ashley-Koch, A.E., Telen, M.J., and Lettre, G. (2021). Potential causal role of l-<br>glutamine in sickle cell disease painful crises: A Mendelian randomization analysis. Blood Cells<br>Mol. Dis. 86, 102504.

ZU. Pincez, T., Lee, S.S.K., Ilboudo, Y., Preuss, M.H., Pham Hung d'Alexandry d'Orengiani, A.-L., Bartolucci, P., Galacteros, F., Joly, P., Bauer, D.E., Loos, R., et al. (2021). Clonal hematopoiesis in sickle cell disease. Blood 138, 2148–2152. Mol. Bis. 86, 102504.<br>20. Pincez, T., Lee, S.:<br>Bartolucci, P., Galacte<br>sickle cell disease. Blo 20. Pincez, T., Lee, S.S.K., Ilboudo, Y., Preuss, M.H., Pham Hung d'Alexandry d'Orengiani, A.-L.,<br>Bartolucci, P., Galacteros, F., Joly, P., Bauer, D.E., Loos, R., et al. (2021). Clonal hematopoiesis in<br>sickle cell disease.

Bartolucci, P., Galacteros, F., P., Joly, P. 2017, 2021, P., Jolyman, Chemicheline, Procentin<br>Sickle cell disease. Blood 138, 2148–2152.<br>21. Bae, H.T., Baldwin, C.T., Sebastiani, P., Telen, M.J., Ashley-Koch, A., Garrett, sickle cell disease. Blood 138, 2148–2132.<br>21. Bae, H.T., Baldwin, C.T., Sebastiani, F<br>W.C., Bean, C.J., Debaun, M.R., Arking,<br>anemia patients: BCL11A and HBS1L-MYB W.C., Bean, C.J., Debaun, M.R., Arking, D.E., et al. (2012). Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans.<br>Blood 120, 1961–1962. M.C., Bean, C., Beaning, Anning, Arking, D.C., C., C., C., Arking, Arking, D.C., D.M. Candian<br>Blood 120, 1961–1962.<br>22. Taliun, D., Harris, D.N., Kessler, M.D., Carlson, J., Szpiech, Z.A., Torres, R., Taliun, S.A.G.,

anemia patients: Biozania mercuri and the major modifiers of HbT in African Americans.<br>Blood 120, 1961–1962.<br>22. Taliun, D., Harris, D.N., Kessler, M.D., Carlson, J., Szpiech, Z.A., Torres, R., Taliun, S.A.G.,<br>Corvelo, A., Blood 120, 1301–1302.<br>22. Taliun, D., Harris, I<br>Corvelo, A., Gogarten, !<br>from the NHLBI TOPMe Corvelo, A., Gogarten, S.M., Kang, H.M., et al. (2021). Sequencing of 53,831 diverse genomes<br>from the NHLBI TOPMed Program. Nature 590, 290–299.<br>23. Chen, M.-H., Raffield, L.M., Mousas, A., Sakaue, S., Huffman, J.E., Mosca

from the NHLBI TOPMed Program. Nature 590, 290–299.<br>23. Chen, M.-H., Raffield, L.M., Mousas, A., Sakaue, S., Huffman, J.E., Moscati, A., Trivedi, B.,<br>Jiang, T., Akbari, P., Vuckovic, D., et al. (2020). Trans-ethnic and Anc from the NHLBI TOTMed Program. Nature 590, 290–299.<br>23. Chen, M.-H., Raffield, L.M., Mousas, A., Sakaue, S.,<br>Jiang, T., Akbari, P., Vuckovic, D., et al. (2020). Trans-ei<br>Genetics in 746,667 Individuals from 5 Global Popula Jiang, T., Akbari, P., Vuckovic, D., et al. (2020). Trans-ethnic and Ancestry-Specific Blood-Cell<br>Genetics in 746,667 Individuals from 5 Global Populations. Cell 182, 1198–1213.e14.

Wojcik, G.L., Shemirani, R., Beckmann, N.D., et al. (2021). Toward a fine-scale population health monitoring system. Cell 184. 2068–2083.e11. 24. Belbin, G.M., Cullina, S., Wenric, S., Soper, E.R., Glicksberg, B.S., Torre, D., Moscati, A., Wojcik, G.L., Shemirani, R., Beckmann, N.D., et al. (2021). Toward a fine-scale population health<br>monitoring system. Cell 184, 2068–2083.e11.<br>25. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., M

Wojcin, Shemirani, M., Shemirani, M., Shan, C.L., Shemirani, M., Pepannet Manni<br>Monitoring system. Cell 184, 2068–2083.e11.<br>D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping momoning system. Cen 184, 2008–2083.e11.<br>25. Bycroft, C., Freeman, C., Petkova, D., Ban<br>D., Delaneau, O., O'Connell, J., et al. (2018).<br>and genomic data. Nature 562, 203–209. D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping<br>and genomic data. Nature 562, 203–209.<br>26. Galarneau, G., Palmer, C.D., Sankaran, V.G., Orkin, S.H., Hirschhorn, J.N., and Lettr

(2010). Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat. Genet. 42, 1049-1051. 2010). Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional<br>genetic variation. Nat. Genet. 42, 1049–1051.<br>27. Bauer, D.E., Kamran, S.C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z

(2022). Fine-mapping at three loci known to an extended feral here is appear to a fetal hemoglobine<br>genetic variation. Nat. Genet. 42, 1049–1051.<br>27. Bauer, D.E., Kamran, S.C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., S genetic variation. Nat. Genet. 42, 1049–1091.<br>27. Bauer, D.E., Kamran, S.C., Lessard, S., Xu<br>Smith, E.C., Pinello, L., et al. (2013). An er<br>variation determines fetal hemoglobin level. S Smith, E.C., Pinello, L., et al. (2013). An erythroid enhancer of BCL11A subject to genetic<br>variation determines fetal hemoglobin level. Science 342, 253–257.

variation determines fetal hemoglobin level. Science 342, 253–257.<br>28. Canver, M.C., Lessard, S., Pinello, L., Wu, Y., Ilboudo, Y., Stern, E.N., Needleman, A.J.,<br>Galactéros, F., Brugnara, C., Kutlar, A., et al. (2017). Var 28. Canver, M.C., Lessard, S., Pinello, L., Wu, Y., Ilboudo, Y., Stern, E.N., Needleman, A.J., Galactéros, F., Brugnara, C., Kutlar, A., et al. (2017). Variant-aware saturating mutagenesis using multiple Cas9 nucleases ide 28. Canver, M.C., Lessard, S., Pinello, L., Wu, Y., Ilboudo, Y., Stern, E.N., Needleman, A.J., multiple Cas9 nucleases identifies regulatory elements at trait-associated loci. Nat. Genet. 49. multiple Cas9 nucleases identifies regulatory elements at trait-associated loci. Nat. Genet. 49,<br>625–634.<br>24 comprehensive tool for rare variant association analysis using sequence data. Bioinformatics<br>32, 1423–1426.<br>30. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of

32, 1423–1426.<br>30. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of<br>genomewide association scans. Bioinformatics 26, 2190–2191. 32, 1423–1426.<br>30. Willer, C.J.,<br>genomewide as: genomewide association scans. Bioinformatics 26, 2190–2191.<br>31. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-

generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7.

S., Bowden, J., Langdon, R., et al. (2018). The IVIR-Base platform supports systematic causal 32. Hemani, G., Zheng, J., Elsworth, B., Wade, K.H., Haberland, V., Baird, D., Laurin, C., Burgess, S., Bowden, J., Langdon, R., et al. (2018). The MR-Base platform supports systematic causal inference across the human phe 33. Winkler, T.W., Justice, A.E., Graff, M., Barata, L., Feitosa, M.F., Chu, S., Czajkowski, J., Esko,<br>33. Winkler, T.W., Justice, A.E., Graff, M., Barata, L., Feitosa, M.F., Chu, S., Czajkowski, J., Esko,

S., Bowden, J., Langdon, J., D., M., Louis, M., Langdon, P., P., Chu, S., Czajkowski, J., Esko, B., Czajkowski, J., Esko, B., Fall, T., Kilpeläinen, T.O., et al. (2015). The Influence of Age and Sex on Genetic Associations 33. Winkler, T.W., Justice, A.E., Graff, M., Barata, L., Feitosa, M.F., Chu, S., Czajkowski, J., Esko, T., Fall, T., Kilpeläinen, T.O., et al. (2015). The Influence of Age and Sex on Genetic Associations with Adult Body Si 33. Winkler, T.W., Justice, A.E., Graff, M., Barata, L., Feitosa, M.F., Chu, S., Czajkowski, J., Esko, with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genet. *11,*<br>e1005378.<br>34. Lettre, G., and Bauer, D.E. (2016). Fetal haemoglobin in sickle-cell disease: from genetic

with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. I LoS Genet. 11,<br>e1005378.<br>34. Lettre, G., and Bauer, D.E. (2016). Fetal haemoglobin in sickle-cell disease: from genetic<br>epidemiology to new the 34. Lettre,<br>epidemiolo<br><sup>35. Deisk. l</sub></sup>

epidemiology to new therapeutic strategies. Lancet 387, 2554–2564.<br>35. Reich, D., Nalls, M.A., Kao, W.H.L., Akylbekova, E.L., Tandon, A., Patterson, N., Mullikin, J.,<br>Hsueh, W.-C., Cheng, C.-Y., Coresh, J., et al. (2009). epidemiology to new therapeutic strategies. Lancet 387, 2334–2564.<br>35. Reich, D., Nalls, M.A., Kao, W.H.L., Akylbekova, E.L., Tandon, A.,<br>Hsueh, W.-C., Cheng, C.-Y., Coresh, J., et al. (2009). Reduced neut<br>African descent Hsueh, W.-C., Cheng, C.-Y., Coresh, J., et al. (2009). Reduced neutrophil count in people of<br>African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines<br>gene. PLoS Genet. 5, e1000360. African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet. 5, e1000360.

Wethers, D.L., Pegelow, C.H., and Gill, F.M. (1998). Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91, 288–294. 36. Ohene-Frempong, K., Weiner, S.J., Sleeper, L.A., Miller, S.T., Embury, S., Moohr, J.W., Wethers, D.L., Pegelow, C.H., and Gill, F.M. (1998). Cerebrovascular accidents in sickle cell<br>disease: rates and risk factors. Blood 91, 288–294.<br>37. Lettre, G., Sankaran, V.G., Bezerra, M.A.C., Araújo, A.S., Uda, M., Sann

Memory, Dialy (1991), Jamy and Day (1991), December accretion in the Unit Dec.<br>disease: rates and risk factors. Blood 91, 288–294.<br>37. Lettre, G., Sankaran, V.G., Bezerra, M.A.C., Araújo, A.S., Uda, M., Sanna, S., Cao, A., disease: rates and risk factors. Blood 91, 288–294.<br>37. Lettre, G., Sankaran, V.G., Bezerra, M.A.C.,<br>Schlessinger, D., Costa, F.F., Hirschhorn, J.N., et al<br>HBS1L-MYB, and beta-globin loci associate with fet Schlessinger, D., Costa, F.F., Hirschhorn, J.N., et al. (2008). DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc. Natl. Ac Schlessinger, D., Costain, The, Millessing, Theory, Politic program, programmed at the Bostan<br>HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle<br>cell disease. Proc. Natl. Acad.

HETE MYE, and beta-globin loci and beta-globin loci and pain themoglobin in since the since the since cell disease. Proc. Natl. Acad. Sci. U. S. A. 105, 11869–11874.<br>38. Rampersaud, E., Kang, G., Palmer, L.E., Rashkin, S.R cen disease. Proc. Natl. Acad. Sci. O. S. A. 105, 11865–11874.<br>38. Rampersaud, E., Kang, G., Palmer, L.E., Rashkin, S.R.,<br>Anghelescu, D., Barton, M., Birch, K., et al. (2021). A polyge<br>pain in pediatric sickle cell disease 38. Rampersaud, E., Kang, G., Palmer, L.E., Rashkin, S.R., Wang, S., Bi, W., Alberts, N.M.,

pain in pediatric sickle cell disease. Blood Adv 5, 2839–2851.<br>39. Sommet, J., Alberti, C., Couque, N., Verlhac, S., Haouari, Z., Mohamed, D., François, M.,<br>Missud, F., Holvoet, L., Elmaleh, M., et al. (2016). Clinical and pain in pediatric sickle cell disease. Blood Adv 5, 2835–2831.<br>39. Sommet, J., Alberti, C., Couque, N., Verlhac, S., Haoua<br>Missud, F., Holvoet, L., Elmaleh, M., et al. (2016). Clinical a<br>cerebral macrovasculopathy in a sic Missud, F., Holvoet, L., Elmaleh, M., et al. (2016). Clinical and haematological risk factors for<br>cerebral macrovasculopathy in a sickle cell disease newborn cohort: a prospective study. Br. J.<br>Haematol. 172. 966–977. Missud, F., Missud, F., Elmand, M., Elmand, M., Elmand, M., Missud, C., Brahman, M., Elmand, Br.<br>Expediant Macrovasculopathy in a sickle cell disease newborn cohort: a prospective study. Br. J.<br>40. Calvet, D., Tuilier, T., Haematol. 172, 966–977.<br>40. Calvet, D., Tuilier, T., Mélé, N., Turc, G., Habibi, A., Abdallah, N.A., Majhadi, L., Hemery, F.,

Haematol. 172, 966–977.<br>40. Calvet, D., Tuilier, T.,  $\frac{1}{20}$ . Calvet, D., T., Mélé, N., Mélé, N., Mélé, N., Majhadi, L., Hemery, F.,  $\frac{1}{25}$ 

silent brain lesions in adults with homozygous sickle cell disease. Blood Adv 1, 2503–2509.<br>41. Nouraie, M., Darbari, D.S., Rana, S., Minniti, C.P., Castro, O.L., Luchtman-Jones, L., Sable, C.,<br>Dham, N., Kato, G.J., Gladwi shent brain lesions in adults with homozygous sickle cell disease. Blood Adv 1, 2505–2505.<br>41. Nouraie, M., Darbari, D.S., Rana, S., Minniti, C.P., Castro, O.L., Luchtman-Jones, L., Sab<br>Dham, N., Kato, G.J., Gladwin, M.T., Dham, N., Kato, G.J., Gladwin, M.T., et al. (2020). Tricuspid regurgitation velocity and other<br>biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the<br>United States: The PUSH study biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the<br>United States: The PUSH study. Am. J. Hematol. 95, 766–774.<br>42. Nader, E., Romana, M., and Connes, P. (2020). The Red Blood

United States: The PUSH study. Am. J. Hematol. *95*, 766–774.<br>42. Nader, E., Romana, M., and Connes, P. (2020). The Red Blood Cell-Inflammation Vicious<br>Circle in Sickle Cell Disease. Front. Immunol. *11*, 454. United States: The PUSH study. Am. J. Hematol. 95, 766–774.<br>42. Nader, E., Romana, M., and Connes, P. (2020). The Red<br>Circle in Sickle Cell Disease. Front. Immunol. 11, 454.

44. Nader, E., Naderstand, M., 2021, N., 2022, N., 2022, N., 2022, N., 2022, N., 2022, N., 2022, S., Gautier, E.-F., Guillonneau, F., Bondet, V., Duffy, D., Dechavanne, S., Tharaux, P.-L., Mayeux, P., Le Van Kim, C., et al Circle in Sickle Cell Disease. Front. Immunol. 11, 454.<br>43. Hermand, P., Azouzi, S., Gautier, E.-F., Guillonnea<br>Tharaux, P.-L., Mayeux, P., Le Van Kim, C., et al. (20<br>cell disease reveals an unexpected activation 44. Hermann, P., Mayeux, P., Journal, P., Pamermeau, P., Pemery, P., Pam, P., P., Pemerine, P., P., Tharaux, P., L., Mayeux, P., Le Van Kim, C., et al. (2020). The proteome of neutrophils in sickle cell disease reveals an Tharaux, P. L., Mayeux, P., L. J. Martin, P., L. Martin, C. L. P. M. Persensis Proteins in Martin Proteins.<br>Thaematologica 105, 2851–2854.<br>44. Peiper, S.C., Wang, Z.X., Neote, K., Martin, A.W., Showell, H.J., Conklyn, M.J.

cell disease reveals an unexpected activation of interferom alpha signaling pathway.<br>Haematologica 105, 2851–2854.<br>Hadley, T.J., Lu, Z.H., Hesselgesser, J., et al. (1995). The Duffy antigen/receptor for chemokines 11aematologica 105, 2051–2054.<br>44. Peiper, S.C., Wang, Z.X., Neo<br>Hadley, T.J., Lu, Z.H., Hesselgesse<br>(DARC) is expressed in endotheli Hadley, T.J., Lu, Z.H., Hesselgesser, J., et al. (1995). The Duffy antigen/receptor for chemokines<br>(DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte<br>receptor. J. Exp. Med. 181, (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte<br>receptor. J. Exp. Med. 181, 1311–1317.<br>45. Tournamille, C., Colin, Y., Cartron, J.P., and Le Van Kim, C. (1995). Disruption of

(DARC) is exp. Med. 181, 1311–1317.<br>The Van Express of Duffy Ass. Tournamille, C., Colin, Y., Cartron, J.P., and Le Van Kim, C. (1995). Disruption of a GATA<br>The Puffy of Duffy and promoter abolishes erythroid gene expressi receptor. J. Exp. Med. 181, 1911–1917.<br>45. Tournamille, C., Colin, Y., Cartron,<br>motif in the Duffy gene promoter a<br>individuals. Nat. Genet. 10, 224–228. motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative<br>individuals. Nat. Genet. 10, 224–228.<br>46. Grann, V.R., Ziv, E., Joseph, C.K., Neugut, A.I., Wei, Y., Jacobson, J.S., Horwitz, M.S.,

individuals. Nat. Genet. 10, 224–228.<br>46. Grann, V.R., Ziv, E., Joseph, C.K., Neugut, A.I., Wei, Y., Jacobson, J.S., Horwitz, M.S.,<br>Bowman, N., Beckmann, K., and Hershman, D.L. (2008). Duffy (Fy), DARC, and neutropenia marviduals. Nat. Genet. 10, 224–228.<br>46. Grann, V.R., Ziv, E., Joseph, C.<br>Bowman, N., Beckmann, K., and He<br>among women from the United Stat. Bowman, N., Beckmann, K., and Hershman, D.L. (2008). Duffy (Fy), DARC, and neutropenia<br>among women from the United States, Europe and the Caribbean. Br. J. Haematol. 143, 288–<br>293. Bowman, N., Bommann, N., and Hershman, D.L. (2009). Duffy (Fy), Darry, and neutropenia<br>among women from the United States, Europe and the Caribbean. Br. J. Haematol. 143, 288–<br>47. Reich, D., Nalls, M.A., Kao, W.H.L., Akylb

among women from the Onted States, Europe and the Canbbean. Br. J. Haematol. 143, 288–<br>293.<br>47. Reich, D., Nalls, M.A., Kao, W.H.L., Akylbekova, E.L., Tandon, A., Patterson, N., Mullikin, J.,<br>Hsueh, W.-C., Cheng, C.-Y., Co 47. R<br>Hsue<br>Africa Hsueh, W.-C., Cheng, C.-Y., Coresh, J., et al. (2009). Reduced neutrophil count in people of<br>African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines<br>gene. PLoS Genet. 5, e1000360. African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines<br>gene. PLoS Genet. 5, e1000360.<br>48. Nalls, M.A., Wilson, J.G., Patterson, N.J., Tandon, A., Zmuda, J.M., Huntsman, S., Garcia, M.,

African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines<br>gene. PLoS Genet. 5, e1000360.<br>Hu, D., Li, R., Beamer, B.A., et al. (2008). Admixture mapping of white cell count: genetic locus gene. PLoS Genet. 5, e1000360.<br>48. Nalls, M.A., Wilson, J.G., Patterson, N.J., Tandon, A., Zmuda, J.M., Huntsman, S., Garcia, M.,<br>Hu, D., Li, R., Beamer, B.A., et al. (2008). Admixture mapping of white cell count: genetic Hu, D., Li, R., Beamer, B.A., et al. (2008). Admixture mapping of white cell count: genetic locus<br>responsible for lower white blood cell count in the Health ABC and Jackson Heart studies. Am. J.<br>Hum. Genet. 82, 81–87. responsible for lower white blood cell count in the Health ABC and Jackson Heart studies. Am. J.<br>Hum. Genet. 82, 81–87.<br>49. Afenyi-Annan, A., Kail, M., Combs, M.R., Orringer, E.P., Ashley-Koch, A., and Telen, M.J.

responsible for a mode of the form in the Health ABC and Jackson March ABC cannot the Health ABC.<br>Hum. Genet. 82, 81–87.<br>(2008). Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion 48, 917-924. (2008). Lack of Duffy antigen expression is associated with organ damage in patients with sickle<br>cell disease. Transfusion 48, 917–924.<br>50. Schaefer, B.A., Flanagan, J.M., Alvarez, O.A., Nelson, S.C., Aygun, B., Nottage, K

(2008). Cell disease. Transfusion 48, 917–924.<br>1908). Schaefer, B.A., Flanagan, J.M., Alvarez, O.A., Nelson, S.C., Aygun, B., Nottage, K.A., George, S.A., George,<br>1998). A., Roberts, C.W., Piccone, C.M., Howard, T.A., et a cell disease. Transfusion 48, 917–924.<br>50. Schaefer, B.A., Flanagan, J.M., Alv.<br>A., Roberts, C.W., Piccone, C.M., How A., Roberts, C.W., Piccone, C.M., Howard, T.A., et al. (2016). Genetic Modifiers of White Blood A., Roberts, C.W., Piccone, C.M., Howard, T.A., et al. (2016). Genetic Modifiers of White Blood

One 11, e0164364.<br>51. Duchene, J., Novitzky-Basso, I., Thiriot, A., Casanova-Acebes, M., Bianchini, M., Etheridge,<br>S.L., Hub, E., Nitz, K., Artinger, K., Eller, K., et al. (2017). Atypical chemokine receptor 1 on One 11, e0104304.<br>51. Duchene, J., Nc<br>S.L., Hub, E., Nitz,<br>nucleated erythroid S.L., Hub, E., Nitz, K., Artinger, K., Eller, K., et al. (2017). Atypical chemokine receptor 1 on<br>nucleated erythroid cells regulates hematopoiesis. Nat. Immunol. 18, 753–761.<br>52. Schnabel, R.B., Baumert, J., Barbalic, M.,

S.L., Hub, E., Nitz, K., Artinger, K., Eller, K., et al. (2017). Atypical chemokine receptor 1 on nucleated erythroid cens regulates hematopoiesis. Nat. Immunol. 18, 753–761.<br>52. Schnabel, R.B., Baumert, J., Barbalic, M., Dupuis, J., Ellinor, P.T., Durda, P., I<br>J.C., Illig, T., Morrison, A.C., et al. (2010). Duffy anti J.C., Illig, T., Morrison, A.C., et al. (2010). Duffy antigen receptor for chemokines (Darc)<br>polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and<br>other inflammatory mediators. Blood 1 J.C., Ing., I.C., Internett, T.L., I.C., 2014, P.L., 2014, A.R., 2014, P.L., P.L., Internettions (Party)<br>J.C., polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and<br>D.C., Moreno Velásq

polymorphism regulates circulating concentrations of monocyte chemochattractant protein-1 and<br>other inflammatory mediators. Blood 115, 5289–5299.<br>Berglund, A., Strawbridge, R.J., Ärnlöv, J., Melander, O., et al. (2015). Du other inhammatory mediators. Blood 115, 5285–5255.<br>53. Moreno Velásquez, I., Kumar, J., Björkbacka, H<br>Berglund, A., Strawbridge, R.J., Ärnlöv, J., Melander, (<br>genetic variant and the association with Interleukin 8 le Berglund, A., Strawbridge, R.J., Ärnlöv, J., Melander, O., et al. (2015). Duffy antigen receptor<br>genetic variant and the association with Interleukin 8 levels. Cytokine 72, 178–184.<br>54. Nebor, D., Durpes, M.C., Mougenel, D

Berglund, A., Strawbridge, M., A., A., A., M., A., A., O., O., O., O., O., O., O., O., Durpes, M.C., Mougenel, D., Mukisi-Mukaza, M., Elion, J., Hardy-Dessources, M.-<br>D., and Romana, M. (2010). Association between Duffy an genetic variant and the association with interleukin 8 levels. Cytokine 72, 178–184.<br>54. Nebor, D., Durpes, M.C., Mougenel, D., Mukisi-Mukaza, M., Elion, J., Hardy-Des<br>D., and Romana, M. (2010). Association between Duffy a 54. Nebor, D., D., D., Mon, Mongolis, D., Manhet Manuel, M., 2014, O., And Romana, M. (2010). Association between Duffy antigen receptor for chemokines expression and levels of inflammation markers in sickle cell anemia pa expression and levels of inflammation markers in sickle cell anemia patients. Clin. Immunol.<br>136, 116–122.<br>55. van Beers, E.J., Yang, Y., Raghavachari, N., Tian, X., Allen, D.T., Nichols, J.S., Mendelsohn, L.,

136, 116–122.<br>55. van Beers, E.J., Yang, Y., Raghavachari, N., Tian, X., Allen, D.T., Nichols, J.S., Mendelsohn, L.,<br>Nekhai, S., Gordeuk, V.R., Taylor, J.G., 6th, et al. (2015). Iron, inflammation, and early death in 136, 116–122.<br>55. van Beers,<br>Nekhai, S., Gor<br>adults with sick Nekhai, S., Gordeuk, V.R., Taylor, J.G., 6th, et al. (2015). Iron, inflammation, and early death in<br>adults with sickle cell disease. Circ. Res. 116, 298–306.<br>56. Drasar, E.R., Menzel, S., Fulford, T., and Thein, S.L. (2013

adults with sickle cell disease. Circ. Res. 116, 298–306.<br>56. Drasar, E.R., Menzel, S., Fulford, T., and Thein, S.L. (2013). The effect of Duffy antigen<br>receptor for chemokines on severity in sickle cell disease. Haematolo adults with sickle cell disease. Circ. Res. 116, 258–306.<br>56. Drasar, E.R., Menzel, S., Fulford, T., and Thein,<br>receptor for chemokines on severity in sickle cell disea.

receptor for chemokines on severity in sickle cell disease. Haematologica 98, e87–e89.<br>57. Afenyi-Annan, A., Kail, M., Combs, M.R., Orringer, E.P., Ashley-Koch, A., and Telen, M.J.<br>(2008). Lack of Duffy antigen expression receptor for chemokines on severity in sickle cell disease. Haematologica 58, e87–e89.<br>57. Afenyi-Annan, A., Kail, M., Combs, M.R., Orringer, E.P., Ashley-Koch, A., and Te<br>(2008). Lack of Duffy antigen expression is associ 57. After, Annan, A., Ann, An, Jerning, Ann, Schinger, 2007, Anne, Aren, An, And Telen, A., A., (2008). Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion 48,

(2008). Lack of Duffy antigent expression is an interest with organ damage in patients with sincle<br>2018). Lack of Duffy and Stein March C. (Mang. L., Ma, Q., Wyszynski, D.F., Farrell, J.J.,<br>2018). Sebastiani, P., Farrer, L cen disease. Transfusion 48, 917–924.<br>58. Nolan, V.G., Adewoye, A., Baldv<br>Sebastiani, P., Farrer, L.A., and Steinb<br>haemolysis and SNPs in Klotho, TEK ar Sebastiani, P., Farrer, L.A., and Steinberg, M.H. (2006). Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br. J. Haematol.<br>133, 570–578. Sebastiani, P., Farrer, L.A., and Steinberg, Milli (2006). During the right level limited that<br>haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br. J. Haematol.<br>59. Elliott, L., Ashley-Koch, A.E.,

haemolysis and SNPs in Reams, Ten and genes of the TGP-beta/BMP, The TGP-beta/BMP pathway.<br>133, 570–578.<br>Brice Weinberg, J., Eckman, J.R., Orringer, E.P., et al. (2007). Genetic polymorphisms associated 133, 370–378.<br>59. Elliott, L., A<br>Brice Weinberg<br>with priapism i Brice Weinberg, J., Eckman, J.R., Orringer, E.P., et al. (2007). Genetic polymorphisms associated<br>with priapism in sickle cell disease. Br. J. Haematol. 137, 262–267.<br>60. Schnog, J.B., Keli, S.O., Pieters, R.A., Rojer, R.A

with priapism in sickle cell disease. Br. J. Haematol. 137, 262–267.<br>60. Schnog, J.B., Keli, S.O., Pieters, R.A., Rojer, R.A., and Duits, A.J. (2000). Duffy phenotype does<br>not influence the clinical severity of sickle cell with priapism in sickle cell disease. Br. J. Haematol. 157, 262–267.<br>60. Schnog, J.B., Keli, S.O., Pieters, R.A., Rojer, R.A., and Duits, A.J.<br>not influence the clinical severity of sickle cell disease. Clin. Immur

61. Farawela, H.M., El-Ghamrawy, M., Farhan, M.S., Soliman, R., Yousry, S.M., and<br>61. Farawela, H.M., El-Ghamrawy, M., Farhan, M.S., Soliman, R., Yousry, S.M., and<br>AbdelRahman, H.A. (2016). Association between Duffy antige not influence the clinical severity of sickle cell disease. Clin. Immunol. 56, 264–266.<br>61. Farawela, H.M., El-Ghamrawy, M., Farhan, M.S., Soliman, R., Yousry,<br>AbdelRahman, H.A. (2016). Association between Duffy antigen re AbdelRahman, H.A. (2016). Association between Duffy antigen receptor expression and disease<br>27 AbdelRahman, H.A. (2016). Association between Duffy antigen receptor expression and disease

severity in sickle cell disease patients. Hematology 21, 474–479.<br>62. Bernaudin, F., Verlhac, S., Arnaud, C., Kamdem, A., Hau, I., I<br>Madhi, F., Fourmaux, C., et al. (2016). Long-term treatment follo<br>disease monitored with Madhi, F., Fourmaux, C., et al. (2016). Long-term treatment follow-up of children with sickle cell<br>disease monitored with abnormal transcranial Doppler velocities. Blood 127, 1814–1822.<br>63. Ware, R.E., Davis, B.R., Schultz

disease monitored with abnormal transcranial Doppler velocities. Blood 127, 1814–1822.<br>63. Ware, R.E., Davis, B.R., Schultz, W.H., Brown, R.C., Aygun, B., Sarnaik, S., Odame, I., Fuh, B.,<br>George, A., Owen, W., et al. disease monitored with abnormal transcration Doppler velocities. Blood 127, 1814–1822.<br>63. Ware, R.E., Davis, B.R., Schultz, W.H., Brown, R.C., Aygun, B., Sarnaik, S., Odame, I., F<br>George, A., Owen, W., et al. (2016). Hydr George, A., Owen, W., et al. (2016). Hydroxycarbamide versus chronic transfusion for<br>maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD<br>With Transfusions Changing to Hydroxyurea (T maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD<br>With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-<br>inferiority trial. Lancet 387, 661–6 maintenance of anti-communicate of transcriber in children with since the international of With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-<br>inferiority trial. Lancet 387, 661–670

 $M_{\rm H}$  Transforms  $C_{\rm H}$  multicentre, open-label, phase 3, non-label, phase 3 inferiority trial. Lancet 387, 661–670.<br>64. Platt, O.S. (2008). Hydroxyurea fo<br>65. Febraid. A.S. Wang, M. Historic

64. Flatt, O.S. (2006). Hydroxyurea for the treatment of sickle cell anemia. N. Engl. J. Med. 358,<br>1362–1369.<br>65. Fahed, A.C., Wang, M., Homburger, J.R., Patel, A.P., Bick, A.G., Neben, C.L., Lai, C.,<br>Brockman, D., Philipp --------<br>65. Fahed,<br>Brockman,<br>penetrance Brockman, D., Philippakis, A., Ellinor, P.T., et al. (2020). Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. Nat. Commun. 11, 3635. penetrance of monogenic variants for tier 1 genomic conditions. Nat. Commun. 11, 3635.



Figure 1. Variance explained by polygenic trait scores (PTS) for hematological traits (HT) in<br>African-ancestry non-sickle cell disease (SCD) individuals from BioMe and the UK Biobank, and participants from three SCD cohorts (CSSCD, GEN-MOD, Mondor/Lyon). We only present the variance explained by nominally significant PTS in at least one SCD cohort (Table 1). When the PTS for a given HT was significant in more than one SCD cohort, we calculated the mean and<br>standard deviation (error bars) of the variance explained. EOS: eosinophils, MCH: mean etandard deviation (error bars) of the variance explained. EOS: eosinophils, MCH: mean<br>corpuscular hemoglobin, MCV: mean corpuscular volume, MON: monocytes, MPV: mean د الله السيار.<br>Corpuscular hemoglobin, MCV: mean corpuscular volume, MON: monocytes, MPV: mean<br>platelet volume, NEU: neutrophil count, PLT: platelet count, RBC: red blood cell count, WBC: platelet volume, NEU: neutrophil count, PLT: platelet count, RBC: red blood cell count, WBC:<br>white blood cell count. plate volume, NEU: neutrophil count, PLT: platelet count, PLT: platelet count, RBC: red blood cell count, RBC: red



Figure 2. Sickle cen disease (SCD) partially masks the genetic impact of the Duffy/DARC null<br>variant (rs2814778) on neutrophil count. (A) Comparison of effect sizes (Beta) for 3,917 SNP-<br>hematological trait pairs in SCD pa variant (152614778) on neutrophil count. (A) Comparison of effect sizes (Beta) for 3,917 SNP-<br>hematological trait pairs in SCD patients (x-axis) and non-SCD participants (y-axis). We only<br>considered variants with a minor a considered variants with a minor allele frequency  $> 1\%$  in the SCD meta-analyses. We highlight two variants with significantly different effect sizes between SCD and non-SCD individuals (see text for details). The blue line represents the best-fit linear regression line. (B) Variance<br>explained (mean and standard deviation) by polygenic trait scores (PTS) for neutrophil (NEU) text for details). The blue line represents the best-fit linear regression line. (**b**) variance<br>explained (mean and standard deviation) by polygenic trait scores (PTS) for neutrophil (NEU)<br>and white blood cell counts (WBC) explained values (meand white blood cell counts (WBC) with and without chromosome (chr) 1 in SCD and non-SCD<br>individuals. (C) Raw neutrophil count (y-axis) as a function of the multi-ancestry NEU PTS and white blood cell counts (WBC) with and white the without (Chr) 2 in SCD and with SCD<br>individuals. (C) Raw neutrophil count (y-axis) as a function of the multi-ancestry NEU PTS<br>(without chr 1 variants, x-axis) in Duffyindividuals. (C) Raw neutrophil count (y-axis) as a function of the multi-ancestry NEU PTS<br>(without chr 1 variants, x-axis) in Duffy-positive (Fy+, T/T or C/T genotypes at rs2814778) and (without chr 1 variants, x-axis) in Duffy-positive  $(F, F, T)$  or C/T genotypes at rs2814778) and<br>30

Duffy-negative (Fy-, C/C genotype) SCD or non-SCD individuals. Regression lines for each of the<br>four subgroups are shown. (D) Comparison of raw neutrophil count between Fy+ individuals with a PTS within the lowest quintile and Fy- individuals with a PTS within the highest quintile. for both SCD and non-SCD participants. ns: non-significant. for both SCD and non-SCD participants. ns: non-significant.



Figure 3. Mendelian randomization (MR) results for fetal hemoglobin (HbF) levels on stroke.<br>Each dot represents one of the HbF-associated SNP, with its corresponding effect on normalized HbF levels (x-axis, standard deviation units) and stroke risk (y-axis, logistic regression beta). The analysis without rs114398597 is significant; see Table S8 for details. regression beta). The analysis without rs114398397 is significant; see Table S8 for details.

Table 1. Hematological trait (HT) variance explained by polygenic trait scores (PTS) in sickle cell disease (SCD) patients. We only calculated the phenotypic variance explained for PTS that were nominally significant (P-value < 0.05). Grey shaded cells indicate phenotypes that were not available in the corresponding study. The <sup>a</sup>PTS models (except for fetal hemoglobin [HbF]) and the results from the  $b$ BioMe African American participants were reported previously.<sup>23</sup> For HbF, we selected six independently associated variants.26–28 MCH: mean corpuscular hemoglobin, MCV: mean corpuscular volume, MPV: mean platelet volume.



Table 2. Genetic association results between the Duffy/DARC null variant (rs2814778) and white blood cell (WBC) and neutrophil counts. The direction of the effect is given for the CC genotype (in a recessive genetic model). Neutrophil count is not available in Mondor/Lyon. Effect sizes (Beta) and standard errors (SE) are in standard deviation units. EAF, effect allele frequency.



Table 3. The polygenic trait score (PTS) for fetal hemoglobin (HbF) levels is associated with stroke and acute chest syndrome (ACS), and improves the prediction of vaso-occlusive crises (VOC) rates. We carried out these analyses in 1,278 genotyped CSSCD participants. To compare predictive models, we performed an analysis of deviance and compared a baseline model (HT, age, sex,  $\alpha$ -thalassemia) with a model that included the same predictors as well as the PTS (Methods).

